<SEC-DOCUMENT>0001206774-12-003833.txt : 20120828
<SEC-HEADER>0001206774-12-003833.hdr.sgml : 20120828
<ACCEPTANCE-DATETIME>20120828070624
ACCESSION NUMBER:		0001206774-12-003833
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20120828
DATE AS OF CHANGE:		20120828

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESEARCH FRONTIERS INC
		CENTRAL INDEX KEY:			0000793524
		STANDARD INDUSTRIAL CLASSIFICATION:	PATENT OWNERS & LESSORS [6794]
		IRS NUMBER:				112103466
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-179099
		FILM NUMBER:		121058306

	BUSINESS ADDRESS:	
		STREET 1:		240 CROSSWAYS PARK DR
		CITY:			WOODBURY
		STATE:			NY
		ZIP:			11797-2033
		BUSINESS PHONE:		5163641902

	MAIL ADDRESS:	
		STREET 1:		240 CROSSWAYS PARK DR
		CITY:			WOODBURY
		STATE:			NY
		ZIP:			11797-2033
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>rfi_424b5.htm
<DESCRIPTION>PROSPECTUS FILED PURSUANT TO RULE 424(B)(5)
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><B><FONT face="Times New Roman" size=2>Prospectus
      Supplement</FONT></B></TD>
    <TD noWrap align=right width="49%"><B><FONT face="Times New Roman" size=2>Filed Pursuant to Rule
      424(b)(5)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><B><FONT face="Times New Roman" size=2>(To Prospectus Dated
      February 14, 2012)</FONT></B></TD>
    <TD noWrap align=right width="49%"><B><FONT face="Times New Roman" size=2>Registration Statement
      No. 333-179099</FONT></B></TD></TR></TABLE><BR>
<P align=center><IMG src="rfi_logo.jpg" border=0></P>
<P align=center><B><FONT face="Times New Roman" size=2>1,900,000 Shares of Common
Stock<BR></FONT></B><B><FONT face="Times New Roman" size=2>380,000 Warrants to Purchase
Common Stock at $4.45 per Share<BR></FONT></B><FONT face="Times New Roman" size=2>___________________</FONT></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>We are offering
1,900,000 shares of our common stock, par value $0.0001 per share, together with
warrants to purchase 380,000 shares of common stock in this offering. This
prospectus supplement also covers the shares of common stock issuable from time
to time upon the exercise of these warrants. Each share of common stock sold in
this offering will be sold with a warrant to purchase 0.20 of a share of common
stock at an exercise price of $4.45 per share (150% of the aggregate offering
price of a share and corresponding warrant). Each share and corresponding
warrant will be sold at an aggregate public offering price of $2.97.</FONT></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Our common stock
is listed on the NASDAQ Capital Market under the symbol &#147;REFR.&#148; We do not intend
to list the warrants to be sold in this offering on any securities exchange. On
August 24, 2012, the last reported sale price of our common stock on the NASDAQ
Capital Market was $2.92 per share.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our principal executive office is located at 240 Crossways Park Drive,
Woodbury, New York 11797. Our telephone number is (516) 364-1902. We do not
intend for information contained on our web site to be part of this prospectus
supplement. </FONT></P>
<P align=left><FONT face="Times New Roman"></FONT><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT><STRONG>Investing in our common stock
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page S-2 of
this prospectus supplement.</STRONG></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-TOP: #000000 2pt double; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="63%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 2pt double; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-TOP: #000000 2pt double; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" >&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-TOP: #000000 2pt double; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="15%"><B><FONT face="Times New Roman" size=2>Per Share
      and<BR>Corresponding Warrant (1) </FONT></B></TD>
    <TD style="BORDER-TOP: #000000 2pt double; BORDER-BOTTOM: #000000 1pt solid" noWrap width="1%" >&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 2pt double; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-TOP: #000000 2pt double; BORDER-BOTTOM: #000000 1pt solid" noWrap width="1%" >&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-TOP: #000000 2pt double; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" width="16%"><STRONG><FONT face="Times New Roman" size=2>Total</FONT></STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="63%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Public offering
      price</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$2.97</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="16%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$5,643,000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="63%"><FONT face="Times New Roman" size=2>Underwriting
      discount</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="15%"><FONT face="Times New Roman" size=2>$0.1782</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" ></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="16%"><FONT face="Times New Roman" size=2>$338,580</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="63%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Proceeds, before
      expenses, to us</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$2.7918</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="16%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$5,304,420</FONT></TD></TR></TABLE>


<BR>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In addition to the underwriting discount, we have agreed to pay up to
$25,000 of the fees and expenses of the underwriter in connection with this
offering. See &#147;Underwriting&#148; beginning on page S-9 of this prospectus
supplement. </FONT></P>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap>&nbsp; </TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Each
      share will be sold with one-fifth of a warrant expiring five years after the closing
      of this offering to purchase common stock at an exercise price of $4.45
      per share.</FONT></TD></TR></TABLE>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT face="Times New Roman" size=2><B>Neither the Securities and Exchange Commission nor
any state securities commission has approved or disapproved of these securities
or determined if this prospectus is truthful or complete. Any representation to
the contrary is a criminal offense.</B></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>The underwriter expects to deliver
the shares of common stock and warrants to the purchasers on or about August
31, 2012. </FONT></P>
<P align=center><I><FONT face="Times New Roman" size=2>Sole Book-Running Manager
</FONT></I></P>
<P align=center><B><FONT face="Times New Roman" size=4>Craig-Hallum Capital Group
</FONT></B></P>
<P align=center><FONT face="Times New Roman" size=2>The date of this prospectus supplement
is August 28, 2012</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>TABLE OF CONTENTS </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>Prospectus Supplement </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>About this Prospectus Supplement</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>S-i</FONT><FONT face="Times New Roman" size=2></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>The Company</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>S-1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>The Offering</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>S-1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>Risk Factors</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>S-2</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Available Information</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>S-7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>Use of Proceeds</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>S-8</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Description of Warrants</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>S-8</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>Underwriting</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>S-9</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Legal Matters</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>S-</FONT><FONT face="Times New Roman" size=2>10</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>Experts</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>S</FONT><FONT face="Times New Roman" size=2>-</FONT><FONT face="Times New Roman" size=2>10</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>Prospectus</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>SUMMARY</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>THE COMPANY</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>RISK FACTORS</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>2</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>AVAILABLE INFORMATION</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>DIVIDENDS</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>USE OF PROCEEDS</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>DESCRIPTION OF SECURITIES</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>PLAN OF DISTRIBUTION</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>8</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>EXPERTS</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>9</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>LEGAL MATTERS</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>9</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>___________________</FONT><B><FONT face="Times New Roman" size=2> </FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2><B>You should
rely only on the information contained in or incorporated by reference in this
prospectus supplement and  the accompanying prospectus. We have not authorized anyone to
provide you with different information. We are not making an offer of these
securities in any state where the offer is not permitted. You should not assume
that the information contained in or incorporated by reference in this
prospectus supplement or the accompanying prospectus is accurate as of any date
other than the date of such document. </B></FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>About this Prospectus
Supplement</FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>This prospectus
supplement and the accompanying base prospectus dated February 14, 2012 are part
of a &#147;shelf&#148; registration statement that we have filed with the Securities and
Exchange Commission, or SEC, and was declared effective by the SEC. Each time we
sell securities under the accompanying base prospectus we will provide a
prospectus supplement that will contain specific information about the terms of
that offering, including the price, the amount of common stock being offered and
the plan of distribution. This prospectus supplement describes the specific
details regarding this offering, including the price, the amount and type of
securities being offered, the risks of investing in our securities and the
underwriting of this offering. The accompanying base prospectus provides general
information about us, some of which, such as the section entitled &#147;Plan of
Distribution,&#148; may not apply to this offering.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If information in this prospectus supplement is inconsistent with the
accompanying base prospectus or the information incorporated by reference, you
should rely on this prospectus supplement. You should read both this prospectus
supplement and the accompanying base prospectus together with the additional
information about Research Frontiers Incorporated that is incorporated by
reference in this prospectus supplement and the accompanying base prospectus.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The following trademarks are property of Research Frontiers: SPD-Smart&#153;,
SPD-SmartGlass&#153;, VaryFast&#153;, SPD-CleanTech&#153;, SPD Clean Technology&#153;, SmartGlass&#153;,
The View of the Future - Everywhere you Look&#153;, Powered by SPD&#153;, Powered by
SPD-CleanTech&#153;, Powered by SPD Clean Technology&#153;, SG Enabled&#153;, SPD Green and
Clean&#153;, SPD On-Board&#153;, Speed Matters&#153;, and Visit SmartGlass.com - to change your
view of the world&#153;. Other trademarks appearing in this prospectus supplement,
the accompanying prospectus and the documents incorporated by reference herein
and therein are property of their respective owners.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-i</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<div style="padding: 10pt; border: 1pt solid black; width: 100%" >

<P align=center><B><FONT face="Times New Roman" size=2>The Company</FONT></B></P>
<P align=left><FONT face="Times New Roman"></FONT>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Research Frontiers Incorporated (together with its subsidiary, &#147;Research
Frontiers,&#148; &#147;we&#148; or the &#147;Company&#148;) develops and licenses its suspended particle
technology for controlling the amount of light passing through a device. Such
suspended particle devices are often referred to as &#147;SPDs,&#148; &#147;light valves,&#148; or
&#147;SPD-Smart&#148; products.</FONT></P>
<P align=left><FONT face="Times New Roman"></FONT><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT>SPDs use microscopic light-absorbing
particles that are either in a liquid suspension or a film. The microscopic
particles align when an electrical voltage is applied. This permits light to
pass through the device, and allows the amount of light to be controlled. Our
offices are located at: 240 Crossways Park Drive, Woodbury, NY 11797 (telephone:
516-364-1902).</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>The Offering</FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="9%"><FONT face="Times New Roman" size=2>Securities offered by
      us:</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top align=left width="89%">
      <P><FONT face="Times New Roman" size=2>1,900,000 shares of common stock together with warrants
      to purchase</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="9%"></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="89%"><FONT face="Times New Roman" size=2>380,000 shares of common
    stock</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="9%"><FONT face="Times New Roman" size=2>Offering price:</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="89%"><FONT face="Times New Roman" size=2>$2.97 per share and corresponding warrant</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="9%"><FONT face="Times New Roman" size=2>Description of the
      warrants:</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="89%"><FONT face="Times New Roman" size=2>The warrants are exercisable at an
      exercise price of $4.45 per share (150% of the aggregate offering price
      for a share of common stock and corresponding warrant) for a period of
      five years beginning on the closing date of this offering. The warrants do
      not allow for cashless exercise. Subject to compliance with any applicable
      securities laws, any portion of a warrant will be transferable upon
      surrender of the warrant. Holders of warrants issued in this offering
      will not be permitted to exercise those warrants for an amount of common
      stock that would result in the holder beneficially owning more than 4.999%
      of our common stock outstanding after the exercise. A warrant holder may
      waive this restriction by providing us written notice of such waiver, but
      any such waiver will not be effective until the 61st day after delivery of
      notice of the waiver to us. Holders of warrants issued in this offering
      will not be permitted to exercise those warrants for an amount of common
      stock that would result in the holder beneficially owning more than 9.999%
      of our common stock outstanding after the exercise. This restriction may
      not be waived. See &#147;Description of Warrants.&#148;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="9%"><FONT face="Times New Roman" size=2>Common Stock
      Outstanding<BR>after this offering:</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=bottom align=left width="89%">
      <P><FONT face="Times New Roman" size=2>21,396,782 shares<sup>(1)</sup></FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="9%"><FONT face="Times New Roman" size=2>Use of Proceeds:</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="89%"><FONT face="Times New Roman" size=2>Working capital and general corporate
      purposes</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="9%"><FONT face="Times New Roman" size=2>NASDAQ Capital
      Market<BR>Symbol:</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=bottom align=left width="89%"><FONT size=2 face="Times New Roman">REFR</FONT></TD></TR></TABLE>____________________<BR>&nbsp;
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The number of shares of common
      stock outstanding after this offering is based upon 19,496,782 shares
      outstanding as of August 27, 2012. It excludes the warrants to be issued
      in this offering, outstanding options and warrants to purchase 1,941,002
      shares of common stock at a weighted average exercise price of $7.41 per
      share, and options or other equity awards for 418,508 shares available
      for future issuance pursuant to the Company&#146;s 2008 Equity Incentive
      Plan.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>S-1</FONT></P></div><br>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>Risk Factors</FONT></B></P>
<P align=left><I><FONT face="Times New Roman"></FONT></I>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2><I>In addition to the other information in this prospectus,
you should carefully consider the following factors in evaluating us and our
business before purchasing the securities offered hereby. This prospectus
supplement, the accompanying prospectus and the information incorporated by
reference in this prospectus supplement and the accompanying prospectus
contains, in addition to historical information, forward-looking statements that
involve risks and uncertainties, some of which are beyond our control. Should
one or more of these risks and uncertainties materialize or should underlying
assumptions prove incorrect, our actual results could differ materially. Factors
that could cause or contribute to such differences include, but are not limited
to, those discussed below, as well as those discussed elsewhere in this
prospectus supplement, the accompany prospectus and the documents incorporated
by reference in this prospectus supplement and the accompanying
prospectus.</I></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><EM>There are risks associated with investing in companies such as ours
who are engaged in research and development. Because of these risks, you should
only invest if you are able to bear the risk of losing your entire investment.
Before investing, in addition to risks which could apply to any issuer or
offering, you should also consider the business we are in and the
following:</EM></FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Source and Need for
Capital.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of June 30, 2012, we had approximately $1.8 million in cash and cash
equivalents. As we take steps in the commercialization and marketing of our
technology, or respond to potential opportunities and/or adverse events, our
working capital needs may change. We anticipate that if our cash and cash
equivalents are insufficient to satisfy our liquidity requirements, we will
require additional funding to sustain our ongoing operations and to continue our
SPD technology research and development activities.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We have funded most of our activities through sales of our common stock
to investors, and upon the exercise of options and warrants. Eventual success of
the Company and generation of positive cash flow will be dependent upon the
extent of commercialization of products using the Company&#146;s technology by the
Company&#146;s licensees and payments of continuing royalties on account thereof. We
can give no assurances that we will generate sufficient revenues in the future
(through sales of our common stock, exercise of options and warrants, royalty
fees, or otherwise) to satisfy our liquidity requirements or sustain future
operations, or that additional funding, if required, will be available when
needed or, if available, on favorable terms.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>History of Operating
Losses.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;  </FONT>We
have experienced net losses from operations, and we may continue to  incur net losses from operations in the future. We
have incurred substantial  costs and expenses in researching and developing our SPD technology. As of June  30, 2012, we had
an accumulative deficit of $86,001,157. Our net loss was $4,134,068 in 2011, $3,874,865 in 2010 and $4,002,761  in
2009 and $1,592,871 for the six  months ended June 30, 2012 (which includes non-cash accounting charge in 2011, 2010 and
2009 of $702,837, $772,604 and $445,913, respectively, and in the six months ended June 30, 2012 of $507,000).</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>We have never declared a cash
dividend and do not intend to declare a cash dividend in the foreseeable
future.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We have never declared or paid cash dividends on our common stock.
Payment of dividends on our common stock is within the discretion of our Board
of Directors and will depend upon our future earnings, capital requirements,
financial condition and other relevant factors. We do not anticipate declaring
or paying any cash dividends on our common stock in the foreseeable
future.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-2</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><I><FONT face="Times New Roman" size=2>We do not directly manufacture or
market products using SPD technology and depend upon activities by our licensees
and their customers.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We depend upon the activities of our licensees in order to be profitable.
We do not directly manufacture or market products using SPD technology. Although
a variety of products have been sold by our licensees, and because it is up to our licensees to decide when
and if they will introduce products using SPD technology, we cannot predict when
and if our licensees will generate substantial sales of such products. Our SPD
technology is currently licensed to 39 companies. Other companies are also
evaluating SPD technology for use in various products. In the past, some
companies have evaluated our technology without proceeding further. While we
expect that our licensees would be primarily responsible for manufacturing and
marketing SPD-Smart products and components, we are also engaging in market
development activities to support our licensees and build the smart glass
industry. We cannot control whether or not our licensees will develop SPD
products. Some of our licensees appear to be more active than others, some
appear to be better capitalized than others, and some licensees appear to be
inactive. There is no guarantee when or if our licensees will successfully
produce any commercial product using SPD technology in sufficient quantities to
make the Company profitable.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>SPD-Smart products have only
recently been introduced.</FONT></I></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Products using
SPD technology have only recently begun to be introduced into the marketplace.
</FONT><FONT face="Times New Roman" size=2>Developing products using new technologies can be
risky because problems, expenses and delays frequently occur, and costs may or
may not come down quickly enough for such products using new technologies to
rapidly penetrate mass market applications.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>SPD-Smart products face intense
competition, which could affect our ability to increase our
revenues.</FONT></I></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>The market for
SPD-Smart products is intensely competitive and we expect competition to
increase in the future. We compete based on the functionality and the quality of
our product. Many of our current and potential competitors have significantly
greater financial, technical, marketing and other resources than we have. In
addition, many of our competitors have well-established relationships with our
current and potential customers and have extensive knowledge of our industry. If
our competitors develop new technologies or new products, improve the
functionality or quality of their current products, or reduce their prices, and
if we are unable to respond to such competitive developments quickly either
because our research and development efforts do not keep pace with our
competitors or because of our lack of financial resources, we may be unable to
compete effectively.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Declining production of automobiles,
airplanes, boats and real estate could harm our business.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our licensees&#146; commercialization efforts of SPD-Smart products could be
negatively impacted if the global production of automobiles, airplanes, boats
and real estate construction declines significantly. If such commercialization
is reduced, our revenues, results of operations and financial condition could be
negatively impacted.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Single source of SPD
film.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our end-product licensees require a source of SPD film to manufacture
finished products. Currently, Hitachi Chemical is the sole source of commercial
quantities of SPD-film. There are several other companies that are licensed to
manufacture SPD-film, but they have not begun commercial production of this
film. Our end-product licensees&#146; ability to sell SPD products could be
negatively impacted if there was a prolonged disruption in SPD-film
availability. Such a disruption could also negatively impact our revenues,
results of operations and financial condition.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>We are dependent on key
personnel.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our continued success will depend, to a significant extent, on the
services of our directors, executive management team, key personnel and certain
key scientists. If one or more of these individuals were to leave the Company,
there is no guarantee that we could replace them with qualified individuals in a
timely or economically satisfactory manner or at all. The loss or unavailability
of any or all of these individuals could harm our ability to execute our
business plan, maintain important business relationships and complete certain
product development initiatives, which would have a material adverse effect on
our business, results of operations and financial conditions.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-3</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=left><B><I><FONT face="Times New Roman" size=2>Dependence on SPD-Smart
technology.</FONT></I></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Because SPD
technology is the only technology we work with, our success depends upon the
viability of SPD technology which has yet to be fully proven. We have not fully
ascertained the performance and long-term reliability of our technology, and
therefore there is no guarantee that our technology will successfully be
incorporated into all of the products which we are targeting for use of SPD
technology. We expect that different product applications for SPD technology
will have different performance and reliability specifications. We expect that
our licensees will primarily be responsible for reliability testing, but that we
may also continue to do reliability testing so that we can more effectively
focus our research and development efforts towards constantly improving the
performance characteristics and reliability of products using SPD
technology.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Our patents and other protective
measures may not adequately protect our proprietary intellectual property, and
we may be infringing on the rights of others.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our intellectual property, particularly our proprietary rights in our SPD
technology, is critical to our success. We have received various patents, and
filed other patent applications, for various applications and aspects of our SPD
technology. In addition, we generally enter into confidentiality and invention
agreements with our employees and consultants. Such patents and agreements and
various other measures we take to protect our intellectual property from use by
others may not be effective for various reasons generally applicable to patents
and their granting and enforcement. In addition, the costs associated with
enforcing patents, confidentiality and invention agreements or other
intellectual property rights may be expensive. Our inability to protect our
proprietary intellectual property rights or gain a competitive advantage from
such rights could harm our ability to generate revenues and, as a result, our
business and operations.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>We have broad discretion in the use
of the proceeds of this offering.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;  </FONT>All of
our net proceeds from this offering will be used, as determined by  management in its sole discretion, for working capital
and other general  corporate purposes. Our management will have broad discretion over the use and  investment of the net
proceeds of this offering and there is no assurance that management&rsquo;s chosen application of proceeds will yield
intended results. You will not have the opportunity, as part of your investment decision, to assess whether our proceeds  are being
used appropriately. Pending application of our proceeds, they might be  placed in investments that do not produce income or
that lose value.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Future sales of our securities could
cause our stock price to decline.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If we or our stockholders sell substantial amounts of our common stock in
the public market, the market price of our common stock could decrease. The perception in the public market that we or our stockholders
might sell shares of our common stock could also depress the market price of our
common stock. 1,972,452 shares of our common stock that will be owned by Robert
L. Saxe, one of our directors, Joseph M. Harary, our President and Chief
Executive Officer, and Seth Van Voorhees, our Chief Financial Officer and Vice
President of Business Development, immediately after completion of this offering
will become eligible for sale in the public markets from time to time, subject
to restrictions under the Securities Act of 1933 following the expiration of
lock-up agreements entered into for the benefit of the underwriter. These
&#147;lock-up&#148; agreements are subject to certain exceptions, including for
non-elected or forced sales of our securities by the stockholder in connection
with margin accounts each maintains with broker-dealers. In addition, the
underwriter may, in its sole discretion and at any time or from time to time,
release all or any portion of the securities subject to the lock-up agreements
for sale in the public and private markets prior to the expiration of the
lock-up. The market price for shares of our common stock may drop significantly
when the restrictions on resale by our existing stockholders lapse or if those
restrictions on resale are waived. A decline in the price of shares of our
common stock might impede our ability to raise capital through the issuance of
additional shares of our common stock or other equity securities.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-4</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><I><FONT face="Times New Roman" size=2>The low trading volume of our common
stock may make it difficult for you to sell your shares at a particular price.</FONT></I></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Although our
common stock is listed on the NASDAQ Capital Market, our common stock has
experienced low trading volume. Reported average daily trading volume in our
common stock for 2012 through August 20, 2012, was approximately 21,000 shares.
There is no assurance that this offering will increase the volume of trading in
our common stock. Limited trading volume subjects our common stock to greater price
volatility and may make it difficult for you to sell your shares at a particular price.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Our ability to use net operating
loss carryforwards might be limited.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At December 31, 2011, we had a net operating loss carryforward for
federal income tax purposes of $55 million, varying amounts of which will expire
in each year from 2012 through 2031. To the extent these net operating loss
carryforwards are available, we intend to use them to reduce any corporate
income tax liability associated with our operations we might have in the future.
Section 382 of the Internal Revenue Code generally imposes an annual limitation
on the amount of net operating loss carryforwards that might be used to offset
taxable income when a corporation has undergone significant changes in stock
ownership. As a result, prior or future changes in ownership could put
limitations on the availability of our net operating loss carryforwards. In
addition, our ability to utilize the current net operating loss carryforwards
might be further limited by the issuance of securities in this offering or
future offerings. To the extent our use of our net operating loss carryforwards
or tax losses is limited, our income could be subject to corporate income tax
earlier than it would if we were able to use net operating loss carryforwards,
which could result in lower profits.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Our organizational documents,
stockholders&#146; rights plan and Delaware law make a takeover of our company more
difficult, which may prevent certain changes in control and limit the market
price of our common stock.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Our certificate of incorporation, bylaws, stockholders&#146; rights plan and
Section 203 of the Delaware General Corporation Law contain provisions that may
have the effect of deterring or delaying attempts by our stockholders to remove
or replace management, engage in proxy contests and effect changes in control.
These provisions of our certificate of incorporation and bylaws
include:</FONT></P>
<UL style="FONT-SIZE: 10pt"><LI><FONT face="Times New Roman" size=2>the authority for our board of directors to issue
  without stockholder approval up to 100,000,000 shares of common stock, that,
  if issued, would dilute the ownership of our stockholders;<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the advance notice requirement for director
  nominations or for proposals that can be acted upon at stockholder
  meetings;<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>a classified board of directors, which may make it
  more difficult for a person who acquires control of a majority of our
  outstanding voting stock to replace all or a majority of our
  directors;<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the ability of our directors to fill any vacancy
  on our board of directors by the affirmative vote of a majority of the
  directors then in office under certain circumstances;<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>limitations on the ability of our stockholders to
  act by written consent;<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>limitations on who may call a
  special meeting of stockholders;<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the prohibition on stockholders accumulating their
  votes for the election of directors;<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the limitation on the removal of any of our
  directors by either an affirmative vote of the continuing directors (as
  defined in our certificate of incorporation) other than the subject director
  or by the affirmative vote of the holders of 80% of our outstanding shares of
  each class of stock having the power to vote in a director
  election;<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the requirement of the affirmative vote of the
  holders of at least 80% of our outstanding shares of each class of stock
  having the power to vote in a director election in order for stockholders to
  adopt, amend or repeal any provision of our certificate of incorporation or
  bylaws, unless the adoption, amendment or repeal is approved by a majority of
  the continuing directors (as defined in our certificate of incorporation) present at a meeting
  at which a quorum of the continuing directors are present;
and<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the requirement, subject to limited exceptions, of
  the affirmative vote of the holders of at least 80% of our outstanding shares
  of each class of stock having the power to vote in a director election in
  order for us to complete certain business combination transactions with
  interested stockholders. </FONT></LI></UL>
<P align=center><FONT face="Times New Roman" size=2>S-5 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>We also have
adopted a stockholders&#146; rights plan designed to deter stockholders from
acquiring shares of stock in excess of 15%. In addition, as a Delaware
corporation, we are subject to Delaware law, including Section 203 of the
Delaware General Corporation Law. In general, Section 203 prohibits a Delaware
corporation from engaging in any business combination with any interested
stockholder for a period of three years following the date that the stockholder
became an interested stockholder unless certain specific requirements are met as
set forth in Section 203.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>These provisions could discourage proxy contests and make it more
difficult for you and other stockholders to elect directors, replace incumbent
management and take other corporate actions. Some provisions in our certificate
of incorporation and bylaws may deter third parties from acquiring us, which may
limit the market price of our common stock or prevent us from consummating a
proposed transaction that our stockholders find to be in their best
interests.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>There is currently no established
trading market for the warrants and we do not expect that one will
develop.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The warrants to be sold in this offering will not be listed on the NASDAQ
Capital Market or any other securities exchange and there is currently no
established trading market for the warrants. We do not intend to make a market
in the warrants and do not expect that one will develop. Therefore, you may have
to hold the warrants you purchase in this offering until such time, if any, as
you wish to exercise the warrants or we redeem them.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>There must be a current prospectus
and state registration in order for you to exercise the
warrants.</FONT></I></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Purchasers of the common stock and warrants in this offering will be able
to exercise the warrants only if a current prospectus relating to the common
stock underlying the warrants is then in effect and only if such securities are
qualified for sale or exempt from qualification under the applicable securities
laws of the states in which the various holders of warrants reside. Although we
will attempt to maintain the effectiveness of a current prospectus covering the
common stock underlying the warrants, there can be no assurance that we will be
able to do so. We will be unable to issue common stock to those persons desiring
to exercise their warrants if a current prospectus covering the common stock
issuable upon the exercise of the warrants is not kept effective or if such
shares are neither qualified nor exempt from qualification in the states in
which the holders of the warrants reside.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-6</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P STYLE="text-align: center"><B><FONT face="Times New Roman" size=2>Available
Information</FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Research
Frontiers files reports, proxy statements and other information with the SEC.
You may read and copy such reports, proxy statements and other information at
the public reference room maintained by the SEC at 100 F Street, N.E.,
Washington, D.C. 20549 and you can obtain information on the operation of the
Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also
maintains an internet web site at http://www.sec.gov that contains reports,
proxy and information statements and other information regarding issuers, such
as Research Frontiers, that file electronically with the SEC. Additional
information about us can also be found at our web site at
http://www.SmartGlass.com. The information on, or that may be accessed through,
our web site is not incorporated by reference into and should not be considered
a part of this prospectus supplement.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The SEC allows us to incorporate by reference the information we file
with them, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is
considered to be part of this prospectus, and later information that we file
with the SEC will automatically update and supersede this information. We
incorporate by reference into this prospectus our:</FONT></P>
<UL style="FONT-SIZE: 10pt"><LI><FONT face="Times New Roman" size=2>annual report on Form 10-K for the fiscal year
  ended December 31, 2011,<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the portions of the proxy statement dated April
  27, 2012 for our annual meeting of stockholders held on June 14, 2012 that
  have been incorporated by reference into our report on Form 10-K for the
  fiscal year ended December 31, 2011,<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>quarterly reports on Form 10-Q for the fiscal
  quarters ended March 31, 2012 and June 30, 2012,<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>current reports on Form 8-K filed with the SEC on
  June 18, 2012, August 2, 2012 and August 28, 2012,<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the description of the capital stock contained in
  the Research Frontiers registration statements on Form 8-A under the
  Securities Exchange Act of 1934 dated July 31, 1995 and February 24, 2003.
  </FONT></LI></UL>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All filings filed by Research Frontiers with the SEC under Sections
13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the initial filing
of this prospectus supplement and prior to the termination of the offering or
sale of all securities offered under this prospectus supplement shall be deemed
to be incorporated by reference into this prospectus supplement (except for
information furnished and not filed with the SEC in a Current Report on Form
8-K).</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We will provide each person to whom this prospectus supplement is
delivered, a copy of any information we have incorporated by reference but have
not delivered along with this prospectus supplement. If you would like a copy of
any document incorporated herein by reference, other than exhibits unless such
exhibits are specifically incorporated by reference in any such document, you
can call or write to us at our principal executive offices: </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>240 Crossways Park Drive, Woodbury, New
York 11797-2033, Attention: Corporate Secretary (telephone: (516) 364-1902). We
will provide this information without charge to any person, including a
beneficial owner, to whom a copy of this prospectus supplement is delivered upon
written or oral request. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No dealer, salesperson or other individual has been authorized to give
any information or to make any representation not contained in or incorporated
by reference in this prospectus or in any supplement to this prospectus. If
given or made, you must not rely on such information or representation as having
been authorized by Research Frontiers. Neither the delivery of this prospectus
nor any sale made hereunder will, under any circumstances, create an implication
that there has not been any change in the affairs of Research Frontiers since
the date of this prospectus or that the information contained herein is correct
or complete as of any time after the date of this prospectus. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The information set forth herein and in all publicly disseminated
information about Research Frontiers, includes &#147;forward-looking statements&#148;
within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe
harbor created by that section. Readers are cautioned not to place undue
reliance on these forward-looking statements as they speak only as of the date
of this prospectus and are not guaranteed. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-7</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=center><B><FONT face="Times New Roman" size=2>Use of Proceeds</FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>We currently
intend to use the net proceeds from this offering for working capital general
corporate purposes, including our internal research and development programs and
possible future acquisitions. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We have not determined the amounts we plan to spend on any of the areas
listed above or the timing of these expenditures. As a result, our management
will have broad discretion to allocate the net proceeds from this offering.
Pending application of the net proceeds as described above, we intend to invest
the net proceeds of the offering in money market funds and other
interest-bearing investments. </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>Description of
Warrants</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each purchaser in this offering will receive a warrant to purchase one
share of our common stock for every five shares of common stock purchased in
this offering, rounded to the nearest whole share. The warrants will be issued
pursuant to warrant agreements executed by us. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each warrant will entitle the holder to purchase one share of common
stock at an exercise price of $4.45 per share. Holders of the warrants may
exercise the warrants at any time from the date of issuance to 4:30 P.M. Woodbury, New
York time on the date that is five years after the closing of this offering,
after which unexercised warrants will become void. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with
specified information, and paying the required amount to the Company in
immediately available cash funds. Upon receipt of the required payment and the
warrant certificate properly completed and duly executed, we will issue and
deliver the number of shares of common stock purchasable upon such exercise. If
fewer than all of the warrants represented by the warrant certificate are
exercised, then we will issue a new warrant certificate for the remaining amount
of warrants. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Warrants provide that unless a holder waives the provision, the
warrantholder may not exercise the warrant to the extent that such exercise will
cause the warrantholder to beneficially own more than 4.999% of the common stock
of the Company then outstanding. In no event may a warrantholder exercise
warrants if such exercise shall cause the warrantholder to own more than 9.999%
of the common stock of the Company then outstanding. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT face="Times New Roman" size=2>The exercise price and the number and type
of securities purchasable upon exercise of warrants are subject to adjustment
upon certain corporate events, including certain combinations, consolidations,
liquidations, mergers, recapitalizations, reclassifications, reorganizations,
stock dividends and stock splits, a sale of all or substantially all of our
assets and certain other events. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No fractional warrant shares will be issued upon exercise of the
warrants. Before exercising their warrants, holders of warrants will not have
any of the rights of holders of common stock, including the right to receive
dividends, if any, or, payments upon our liquidation, dissolution or winding up
or to exercise voting rights, if any. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-8</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>Underwriting</FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>The underwriter
named below has agreed to buy, subject to the terms of the underwriting
agreement, the number of securities listed opposite its name below. The
underwriter is committed to purchase and pay for all of the securities if any
are purchased. The underwriting agreement also provides that if the underwriter
defaults, this offering of our securities may be terminated.</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" ALIGN="CENTER" STYLE="line-height: 14pt; border-collapse: collapse; width: 90%">

  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left; width: 96%"></TD>
    <TD NOWRAP STYLE="text-align: center; width: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD NOWRAP STYLE="text-align: center; width: 1%"></TD>
    <TD NOWRAP STYLE="text-align: center; width: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD NOWRAP STYLE="text-align: center; width: 1%"><B><FONT face="Times New Roman" size=2>Number
  of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left"></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="text-align: center"><B><FONT face="Times New Roman" size=2>Shares
  of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left"></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="text-align: center"><B><FONT face="Times New Roman" size=2>Number of</FONT></B></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="text-align: center"><B><FONT face="Times New Roman" size=2>Common
    Stock</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left"></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="text-align: center"><B><FONT face="Times New Roman" size=2>Shares of</FONT></B></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="text-align: center"><B><FONT face="Times New Roman" size=2>Underlying</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="border-bottom: #000000 1pt solid; text-align: left"><B><FONT face="Times New Roman" size=2>Underwriter</FONT></B></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="border-bottom: #000000 1pt solid; text-align: center"><B><FONT face="Times New Roman" size=2>Common Stock</FONT></B></TD>
    <TD NOWRAP STYLE="text-align: center"></TD>
    <TD NOWRAP STYLE="border-bottom: #000000 1pt solid; text-align: center"><B><FONT face="Times New Roman" size=2>Warrants </FONT></B><U><FONT face="Times New Roman" size=1></FONT></U></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left; background-color: #c0c0c0"><FONT face="Times New Roman" size=2>Craig-Hallum Capital
      Group</FONT></TD>
    <TD NOWRAP STYLE="text-align: right; background-color: #c0c0c0"></TD>
    <TD NOWRAP STYLE="background-color: #c0c0c0; text-align: right"><FONT face="Times New Roman" size=2>1,900,000</FONT></TD>
    <TD NOWRAP STYLE="text-align: center; background-color: #c0c0c0"></TD>
    <TD NOWRAP STYLE="background-color: #c0c0c0; text-align: right"><FONT face="Times New Roman" size=2>380,000</FONT><FONT face="Times New Roman" size=2></FONT></TD></TR></TABLE><BR>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>The underwriter
has advised us that it proposes to offer the shares of common stock and
corresponding warrants to the public at an aggregate price of $2.97 per share
and corresponding warrant. Each purchaser of a share of common stock will be
required to purchase a corresponding warrant to purchase 0.20 of a share of
common stock in this offering. The underwriter proposes to offer the securities
to be sold in this offering to certain dealers at the same prices less an
aggregate concession of not more than $0.10692 for each share and corresponding
warrant. After the offering, these figures may be changed by the
underwriter.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The table below summarizes the underwriting discounts that we will pay to
the underwriter. In addition to the underwriting discount, we have agreed to pay
up to $25,000 of the fees and expenses of the underwriter, which may include the
fees and expenses of counsel to the underwriter. The fees and expenses of the
underwriter that we have agreed to reimburse are not included in the
underwriting discounts set forth in the table below.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The underwriter has not received and will not receive from us any other
item of compensation or expense in connection with this offering considered by
the Financial Industry Regulatory Authority to be underwriting compensation
under its rule of fair price. The underwriting discount and other items of
compensation the underwriter will receive were determined through arms&#146; length
negotiations between us and the underwriter.</FONT></P>
<TABLE style="WIDTH: 90%; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 align=center border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: left" noWrap></TD>
    <TD style="TEXT-ALIGN: center" noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=2>Per Share
      and<BR>Corresponding Warrant</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" noWrap><B><FONT face="Times New Roman" size=2>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="WIDTH: 95%; BACKGROUND-COLOR: #c0c0c0; TEXT-ALIGN: left" noWrap><FONT face="Times New Roman" size=2>Underwriting discount to be
      paid to the underwriter by us</FONT></TD>
    <TD style="WIDTH: 1%; BACKGROUND-COLOR: #c0c0c0; TEXT-ALIGN: center" noWrap></TD>
    <TD style="WIDTH: 3%; BACKGROUND-COLOR: #c0c0c0; TEXT-ALIGN: right" noWrap><FONT face="Times New Roman" size=2>$0.1782</FONT></TD>
    <TD style="WIDTH: 1%; BACKGROUND-COLOR: #c0c0c0; TEXT-ALIGN: center" noWrap></TD>
    <TD style="WIDTH: 1%; BACKGROUND-COLOR: #c0c0c0; TEXT-ALIGN: center" noWrap align=right><FONT face="Times New Roman" size=2>$338,580</FONT></TD></TR></TABLE>
<BR>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>We estimate that
the total expenses of the offering, excluding underwriting discounts and
commissions, will be $90,000. This includes $25,000 of fees and expenses of the
underwriter. These expenses are payable by us. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We have agreed to indemnify the underwriter against certain liabilities,
including civil liabilities under the Securities Act, or to contribute to
payments that the underwriter may be required to make in respect of those
liabilities.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Robert L. Saxe, one of our directors, Joseph M. Harary, our President and
Chief Executive Officer, and Seth Van Voorhees, our Chief Financial Officer and
Vice President of Business Development, have agreed not to offer, sell, agree to
sell, directly or indirectly, or otherwise dispose of any shares of common stock
or any securities convertible into or exchangeable for shares of common stock
without the prior written consent of the underwriter for a period of 30 days
after the date of this prospectus supplement. These &#147;lock-up&#148; agreements cover
approximately an aggregate of 1,972,452 shares of our common stock and are
subject to certain exceptions, including for non-elected or forced sales of our
securities by such person in connection with margin accounts each maintains with
broker-dealers and for which shares of our common stock serve as collateral with
respect to such accounts. Each of Messrs. Saxe, Harary and Van Voorhees has
agreed to take all steps reasonably available to prevent any such non-elected or
forced sale.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We have agreed to certain restrictions on our ability to sell additional
shares of our common stock for a period of 30 days after the date of this
prospectus supplement. We have agreed not to offer, sell, agree to sell,
directly or indirectly, or otherwise issue or dispose of, any shares of common
stock, securities convertible into or exchangeable for shares of common stock,
or any related security or instrument, without the prior written consent of the
underwriter. The agreement is subject to limited exceptions. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-9</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>To facilitate the
offering, the underwriter may engage in transactions that stabilize, maintain or
otherwise affect the price of the common stock during and after the offering.
Specifically, the underwriter may over-allot or otherwise create a short
position in the common stock for its own account by selling more shares than
have been sold to it by us. The underwriter may elect to cover any such short
position by purchasing shares of common stock in the open market. In addition,
the underwriter may stabilize or maintain the price of the common stock by
bidding for or purchasing shares of common stock in the open market and may
impose penalty bids. If penalty bids are imposed, selling concessions allowed to
broker-dealers participating in the offering are reclaimed if shares of common
stock previously distributed in the offering are repurchased, whether in
connection with stabilization transactions or otherwise. The effect of these
transactions may be to stabilize or maintain the market price of the common
stock at a level above that which might otherwise prevail in the open market.
The imposition of a penalty bid may also affect the price of the common stock to
the extent that it discourages resales of the common stock. The magnitude or
effect of any stabilization or other transactions is uncertain. These
transactions may be effected on the NASDAQ Stock Market or otherwise and, if
commenced, may be discontinued at any time. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In connection with this offering, the underwriter (and selling group
members) may also engage in passive market making transactions in the common
stock on the NASDAQ Stock Market. Passive market making consists of displaying
bids on the NASDAQ Stock Market limited by the prices of independent market
makers and effecting purchases limited by those prices in response to order
flow. Rule 103 of Regulation M promulgated by the SEC limits the amount of net
purchases that each passive market maker may make and the displayed size of each
bid. Passive market making may stabilize the market price of the common stock at
a level above that which might otherwise prevail in the open market and, if
commenced, may be discontinued at any time. </FONT><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The underwriter may facilitate the marketing of this offering online
directly or through one of its affiliates. In those cases, prospective investors
may view offering terms and a prospectus online and place orders online or
through their financial advisors.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>Legal Matters </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The legality of the securities offered hereby has been passed upon by the
law firm of Duane Morris LLP. As of the August 24, 2012, Victor F. Keen, a
Director of the Company and Of Counsel to Duane Morris LLP owns 293,639 shares
of the Company&#146;s Common Stock directly, 48,160 shares of Common Stock in his
IRA, and holds options and warrants to purchase 67,500 shares of the Company&#146;s
Common Stock. The underwriter has been represented in connection with this
offering by Faegre Baker Daniels LLP, Minneapolis, Minnesota. </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>Experts </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The financial statements and schedule of Research Frontiers as of
December 31, 2011 and 2010, and for each of the three years in the period ended
December 31, 2011, and management&#146;s assessment of the effectiveness over
internal controls as of December 31, 2011, incorporated by reference into this
prospectus supplement have been so incorporated in reliance upon the reports of
BDO USA, LLP, an independent registered public accounting firm, incorporated
herein by reference, given on the authority of said firm as experts in
accounting and auditing. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>S-10</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><FONT face="Times New Roman" size=2>PROSPECTUS</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>RESEARCH FRONTIERS
INCORPORATED</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>3,000,000 Shares</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Common
Stock<BR>___________________</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Research Frontiers Incorporated may from
time to time issue up to 3,000,000 shares of common stock, and/or warrants to
purchase such common stock. A general description of the known material terms of
the securities we are offering is included herein. We will specify in an
accompanying prospectus supplement any specific material terms of the securities
offered which are unknown as of the date of this prospectus. We may sell these
securities to or through underwriters and also to other purchasers or through
agents. We will set forth the names of any underwriters or agents in the
accompanying prospectus supplement.</FONT></P>
<P align=left><FONT face="Times New Roman"></FONT>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Our common stock is listed on the Nasdaq Capital Market under the symbol
&#147;REFR.&#148; The last reported sale price of our common stock on the Nasdaq Capital
Market on January 18, 2012 was $3.73.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>___________________ </FONT></P>
<P align=left><FONT face="Times New Roman"></FONT>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Investing in our common stock involves a high degree of risk.
See &#145;Risk Factors&#146; beginning on page 3.</FONT></p>
<P STYLE="text-align: center"><FONT face="Times New Roman" size=2>___________________</FONT></P>
<P align=left><FONT face="Times New Roman"></FONT>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>This prospectus may not be used to
consummate a sale of securities unless it is accompanied by a prospectus
supplement.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>The date of this prospectus is February
14, 2012</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>SUMMARY</FONT><FONT face="Times New Roman">
</FONT></P>
<P align=left><FONT face="Times New Roman"></FONT><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT>You should read the entire prospectus,
including the section entitled &#145;Risk Factors,&#146; carefully before making an
investment decision.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>THE COMPANY</FONT><FONT face="Times New Roman">
</FONT></P>
<P align=left><FONT face="Times New Roman"></FONT><FONT face="Times New Roman" size=2><FONT size=3 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Research Frontiers Incorporated
(&#147;Research Frontiers&#148; or the &#147;Company&#148;) develops and licenses its suspended
particle technology for controlling the amount of light passing through a
device. Such suspended particle devices are often referred to as &#147;SPDs,&#148; &#147;light
valves,&#148; or &#147;SPD-Smart &#147; products.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>1</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>SPDs use
microscopic light-absorbing particles that are either in a liquid suspension or
a film. The microscopic particles align when an electrical voltage is applied.
This permits light to pass through the device, and allows the amount of light to
be controlled. Our offices are located at: 240 Crossways Park Drive, Woodbury,
NY 11797 (telephone: 516-364-1902).</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>RISK FACTORS</FONT></P>
<P align=left><FONT face="Times New Roman"></FONT>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>In addition to the other information in this prospectus, you should
carefully consider the following factors in evaluating us and our business
before purchasing the shares of common stock offered hereby. This prospectus
contains, in addition to historical information, forward-looking statements that
involve risks and uncertainties, some of which are beyond our control. Should
one or more of these risks and uncertainties materialize or should underlying
assumptions prove incorrect, our actual results could differ materially. Factors
that could cause or contribute to such differences include, but are not limited
to, those discussed below, as well as those discussed elsewhere in this
prospectus, including the documents incorporated by reference.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>There are risks associated with investing
in companies such as ours who are engaged in research and development. Because
of these risks, you should only invest if you are able to bear the risk of
losing your entire investment. Before investing, in addition to risks which
could apply to any issuer or offering, you should also consider the business we
are in and the following:</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Source and Need for Capital.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>As of September 30, 2011, we had
approximately $4.7 million in cash, cash equivalents and bank certificates of
deposits. As we take steps in the commercialization and marketing of our
technology, or respond to potential opportunities and/or adverse events, our
working capital needs may change. We anticipate that if our cash and cash
equivalents are insufficient to satisfy our liquidity requirements, we will
require additional funding to sustain our ongoing operations and to continue our
SPD technology research and development activities.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We have funded most of our activities
through sales of our common stock to investors, and upon the exercise of options
and warrants. Eventual success of the Company and generation of positive cash
flow will be dependent upon the extent of commercialization of products using
the Company&#146;s technology by the Company&#146;s licensees and payments of continuing
royalties on account thereof. We can give no assurances that we will generate
sufficient revenues in the future (through sales of our common stock, exercise
of options and warrants, royalty fees, or otherwise) to satisfy our liquidity
requirements or sustain future operations, or that additional funding, if
required, will be available when needed or, if available, on favorable
terms.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>History of Operating Losses.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We have experienced net losses from
operations, and we may continue to incur net losses from operations in the
future. We have incurred substantial costs and expenses in researching and
developing our SPD technology. As of September 30, 2011, we had a cumulative net
loss of $83,584,461 since our inception. Our net loss was $3,874,865 in 2010,
$4,002,761 in 2009 and $2,594,843 in 2008 (which includes non-cash accounting
charge in 2010, 2009 and 2008 of $772,604, $445,913, and $126,408, respectively,
resulting from the expensing of stock options).</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>2 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>We have never declared a cash dividend and
do not intend to declare a cash dividend in the foreseeable future.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We have never declared or paid cash
dividends on our common stock. Payment of dividends on our common stock is
within the discretion of our Board of Directors and will depend upon our future
earnings, capital requirements, financial condition and other relevant factors.
We do not anticipate declaring or paying any cash dividends on our common stock
in the foreseeable future.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We do not directly manufacture or market
products using SPD technology and depend upon activities by our licensees and
their customers.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We depend upon the activities of our
licensees in order to be profitable. We do not directly manufacture or market
products using SPD technology. Although a variety of products have been sold by
our licensees, and because it is up to our licensees to decide when and if they
will introduce products using SPD technology, we cannot predict when and if our
licensees will generate substantial sales of such products. Our SPD technology
is currently licensed to 39 companies. Other companies are also evaluating SPD
technology for use in various products. In the past, some companies have
evaluated our technology without proceeding further. While we expect that our
licensees would be primarily responsible for manufacturing and marketing
SPD-Smart products and components, we are also engaging in market development
activities to support our licensees and build the smart glass industry. We
cannot control whether or not our licensees will develop SPD products. Some of
our licensees appear to be more active than others, some appear to be better
capitalized than others, and some licensees appear to be inactive. There is no
guarantee when or if our licensees will successfully produce any commercial
product using SPD technology in sufficient quantities to make the Company
profitable.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>SPD-Smart products have only recently been
introduced.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Products using SPD technology have only
recently begun to be introduced into the marketplace. Developing products using
new technologies can be risky because problems, expenses and delays frequently
occur, and costs may or may not come down quickly enough for such products using
new technologies to rapidly penetrate mass market applications.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>SPD-Smart products face intense
competition, which could affect our ability to increase our revenues.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The market for SPD-Smart products is
intensely competitive and we expect competition to increase in the future. We
compete based on the functionality and the quality of our product. Many of our
current and potential competitors have significantly greater financial,
technical, marketing and other resources than we have. In addition, many of our
competitors have well-established relationships with our current and potential
customers and have extensive knowledge of our industry. If our competitors
develop new technologies or new products, improve the functionality or quality
of their current products, or reduce their prices, and if we are unable to
respond to such competitive developments quickly either because our research and
development efforts do not keep pace with our competitors or because of our lack
of financial resources, we may be unable to compete effectively.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Declining production of automobiles,
airplanes, boats and real estate could harm our business.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>3</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>Our licensees&#146; commercialization efforts
of SPD-Smart products could be negatively impacted if the global production of
automobiles, airplanes, boats and real estate construction declines
significantly. If such commercialization is reduced, our revenues, results of
operations and financial condition could be negatively impacted.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Single source of SPD film.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Our end-product licensees require a source
of SPD film to manufacture finished products. Currently, Hitachi Chemical is the
sole source of commercial quantities of SPD-film. There are several other
companies that are licensed to manufacture SPD-film, but they have not begun
commercial production of this film. Our end-product licensees&#146; ability to sell
SPD products could be negatively impacted if there was a prolonged disruption in
SPD-film availability. Such a disruption could also negatively impact our
revenues, results of operations and financial condition.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We are dependent on key
personnel.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Our continued success will depend, to a
significant extent, on the services of our directors, executive management team,
key personnel and certain key scientists. If one or more of these individuals
were to leave the Company, there is no guarantee that we could replace them with
qualified individuals in a timely or economically satisfactory manner or at all.
The loss or unavailability of any or all of these individuals could harm our
ability to execute our business plan, maintain important business relationships
and complete certain product development initiatives, which would have a
material adverse effect on our business, results of operations and financial
conditions.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Dependence on SPD-Smart
technology.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Because SPD technology is the only
technology we work with, our success depends upon the viability of SPD
technology which has yet to be fully proven. We have not fully ascertained the
performance and long-term reliability of our technology, and therefore there is
no guarantee that our technology will successfully be incorporated into all of
the products which we are targeting for use of SPD technology. We expect that
different product applications for SPD technology will have different
performance and reliability specifications. We expect that our licensees will
primarily be responsible for reliability testing, but that we may also continue
to do reliability testing so that we can more effectively focus our research and
development efforts towards constantly improving the performance characteristics
and reliability of products using SPD technology.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Our patents and other protective measures
may not adequately protect our proprietary intellectual property, and we may be
infringing on the rights of others.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Our intellectual property, particularly
our proprietary rights in our SPD technology, is critical to our success. We
have received various patents, and filed other patent applications, for various
applications and aspects of our SPD technology. In addition, we generally enter
into confidentiality and invention agreements with our employees and
consultants. Such patents and agreements and various other measures we take to
protect our intellectual property from use by others may not be effective for
various reasons generally applicable to patents and their granting and
enforcement. In addition, the costs associated with enforcing patents,
confidentiality and invention agreements or other intellectual property rights
may be expensive. Our inability to protect our proprietary intellectual property
rights or gain a competitive advantage from such rights could harm our ability
to generate revenues and, as a result, our business and operations.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>4</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><FONT face="Times New Roman" size=2>AVAILABLE INFORMATION</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Research Frontiers files reports, proxy
statements and other information with the Securities and Exchange Commission.
You may read and copy such reports, proxy statements and other information at
the public reference room maintained by the SEC at 100 F Street, N.E.,
Washington, D.C. 20549 and you can obtain information on the operation of the
Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also
maintains an internet web site at http://www.sec.gov that contains reports,
proxy and information statements and other information regarding issuers, such
as Research Frontiers, that file electronically with the SEC. Additional
information about us can also be found at our web site at
http://www.SmartGlass.com.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The SEC allows us to incorporate by
reference the information we file with them, which means that we can disclose
important information to you by referring you to those documents. The
information incorporated by reference is considered to be part of this
prospectus, and later information that we file with the SEC will automatically
update and supersede this information. We incorporate by reference into this
prospectus our:</FONT></P>
<UL style="margin-left: 16px; FONT-SIZE: 10pt" type=circle><LI><FONT face="Times New Roman" size=2>annual report on Form 10-K for the fiscal year
  ended December 31, 2010,<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the portions of the proxy statement dated April
  29, 2011 for our annual meeting of stockholders to be held on June 9, 2011
  that have been incorporated by reference into our report on Form 10-K for the
  fiscal year ended December 31, 2010,<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>quarterly reports on Form 10-Q for the fiscal
  quarters ended March 31, 2011, June 30, 2011 and September 30,
  2011.<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>current reports on Form 8-K filed with the SEC on
  4/6/2010, 5/19/2010, 6/14/2010, 9/17/2010, 9/27/2010, 12/1/2010, 12/14/2010, 1/3/2011, 1/28/2011, 2/7/2011, 2/9/2011, 4/25/2011, 6/10/2011, 6/27/2011, 9/15/2011, 10/17/2011, 12/15/2011 and 1/10/2012
  and<BR>&nbsp;</FONT>
  </LI><LI><FONT face="Times New Roman" size=2>the description of the capital stock contained in
  the Research Frontiers registration statements on Form 8-A under the
  Securities Exchange Act of 1934 dated July 31, 1995 and February 24,
  2003.</FONT></LI></UL>
<P align=left><FONT face="Times New Roman" size=2>All filings filed by Research Frontiers
with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act
subsequent to the initial filing of this prospectus and prior to the termination
of the offering or sale of all of common stock offered under this prospectus
shall be deemed to be incorporated by reference into this prospectus.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>This prospectus is part of a registration
statement we filed with the SEC. As permitted by the SEC, this prospectus does
not contain all of the information set forth in the registration statement and
the exhibits and schedules thereto. The statements contained in this prospectus
as to the contents of any contract or any other document are not necessarily
complete. In each case you should refer to the copy of such contract or document
filed as an exhibit to the registration statement.</FONT></P>

<P align=center><FONT face="Times New Roman" size=2>5</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>We will provide each person to whom this
prospectus is delivered, a copy of any information we have incorporated by
reference but have not delivered along with this prospectus. If you would like a
copy of any document incorporated herein by reference, other than exhibits
unless such exhibits are specifically incorporated by reference in any such
document, you can call or write to us at our principal executive
offices:</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>240 Crossways Park Drive, Woodbury, New
York 11797-2033, Attention: Corporate Secretary (telephone: (516) 364-1902). We
will provide this information without charge to any person, including a
beneficial owner, to whom a copy of this prospectus is delivered upon written or
oral request.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>No dealer, salesperson or other individual
has been authorized to give any information or to make any representation not
contained in or incorporated by reference in this prospectus or in any
supplement to this prospectus. If given or made, you must not rely on such
information or representation as having been authorized by Research Frontiers.
Neither the delivery of this prospectus nor any sale made hereunder will, under
any circumstances, create an implication that there has not been any change in
the affairs of Research Frontiers since the date of this prospectus or that the
information contained herein is correct or complete as of any time after the
date of this prospectus.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>This prospectus and any supplement to this
prospectus do not constitute an offer to sell or a solicitation of an offer to
buy any securities offered hereby to any person, or by anyone, in any
jurisdiction in which such offer or solicitation may not lawfully be
made.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The information set forth herein and in
all publicly disseminated information about Research Frontiers, includes
&#147;forward-looking statements&#148; within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and is subject to the safe harbor created by
that section. Readers are cautioned not to place undue reliance on these
forward-looking statements as they speak only as of the date of this prospectus
and are not guaranteed.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>DIVIDENDS</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Research Frontiers has never paid any cash
dividends and does not expect to pay any cash dividends for the foreseeable
future.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>USE OF PROCEEDS</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Unless we indicate otherwise in the
applicable prospectus supplement, we currently intend to use the net proceeds
from this offering for general corporate purposes, including our internal
research and development programs, general working capital and possible future
acquisitions.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We have not determined the amounts we plan
to spend on any of the areas listed above or the timing of these expenditures.
As a result, our management will have broad discretion to allocate the net
proceeds from this offering. Pending application of the net proceeds as
described above, we intend to invest the net proceeds of the offering in money
market funds and other interest-bearing investments.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>DESCRIPTION OF SECURITIES</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We may sell from time to time, in one or
more offerings common stock and/or warrants to purchase common stock.</FONT></P>
<P STYLE="text-align: left"><FONT face="Times New Roman" size=2>DESCRIPTION OF COMMON STOCK</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Research Frontiers can issue 100,000,000
shares of common stock, $0.0001 par value per share. 18,907,555 shares were
outstanding as of the date of this prospectus. Holders of common stock are
entitled to one vote per share on matters submitted to shareholders for their
approval, to dividends if declared by Research Frontiers, and to share in any
distribution of Research Frontiers&#146; assets. All outstanding shares of common
stock are fully paid for and non-assessable. Holders of common stock do not have
cumulative voting rights or preemptive rights. Therefore, a minority stockholder
may be less able to gain representation on Research Frontiers&#146; board of
directors.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>6</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>Listing</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Our common stock is listed on the Nasdaq
Capital Market under the symbol &#147;REFR&#148;.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Transfer Agent and Registrar</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Continental Stock Transfer and Trust
Company is the transfer agent and registrar for our common stock.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>DESCRIPTION OF WARRANTS</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The following description sets forth
certain general terms and provisions of the warrants to which any prospectus
supplement may relate. The particular terms of the warrants offered, the extent,
if any, to which the general terms set forth below apply to the warrants
offered, and any modifications or additions to the general terms as they relate
to the warrants offered will be described in a prospectus supplement.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>General</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We may issue warrants for the purchase of
common stock from time to time, and we may issue warrants independently or
together with common stock, and the warrants may be attached to or separate from
these securities.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We will describe in the applicable
prospectus supplement the terms of the series of warrants, including:</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>-the offering price and aggregate number
of warrants offered;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>-the number of shares of common stock
purchasable upon the exercise of one warrant and the price at which these shares
may be purchased upon such exercise;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>-the dates on which the right to exercise
the warrants will commence and expire;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>-the effect of any merger, consolidation,
sale or other disposition of our business on the warrant agreement and the
warrants;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>-the terms of any rights to redeem or call
the warrants;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>-any provisions for changes to or
adjustments in the exercise price or number of securities issuable upon exercise
of the warrants;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>-to the extent material, federal income
tax consequences of holding or exercising the warrants;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>-any other specific terms, preferences,
rights or limitations of or restrictions on the warrants.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Before exercising their warrants, holders
of warrants will not have any of the rights of holders of common stock,
including the right to receive dividends, if any, or, payments upon our
liquidation, dissolution or winding up or to exercise voting rights, if
any.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>7</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>Exercise of Warrants</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Each warrant will entitle the holder to
purchase the securities that we specify in the applicable prospectus supplement
at the exercise price that we describe in the applicable prospectus supplement.
Unless we otherwise specify in the applicable prospectus supplement, holders of
the warrants may exercise the warrants at any time up to 6:00 P.M. Woodbury, New
York time on the expiration date that we set forth in the applicable prospectus
supplement. After the close of business on the expiration date, unexercised
warrants will become void.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Holders of the warrants may exercise the
warrants by delivering the warrant certificate representing the warrants to be
exercised together with specified information, and paying the required amount to
the Company in immediately available funds. Upon receipt of the required payment
and the warrant certificate properly completed and duly executed, we will issue
and deliver the number of shares of common stock purchasable upon such exercise.
If fewer than all of the warrants represented by the warrant certificate are
exercised, then we will issue a new warrant certificate for the remaining amount
of warrants. Unless we indicate otherwise in the applicable prospectus
supplement, holders of the warrants may surrender securities as all or part of
the exercise price for warrants.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>PLAN OF DISTRIBUTION</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We may sell the securities being offered
hereby in one or more of the following ways from time to time:</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- through dealers or agents to the public
or to investors;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- to underwriters for resale to the public
or to investors;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- directly to investors; or</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- through a combination of such
methods.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>We will set forth in a prospectus
supplement the terms of the offering of securities, including:</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- the name or names of any agents, dealers
or underwriters;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- the purchase price of the securities
being offered and the proceeds we will receive from the sale;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- any over-allotment options under which
underwriters may purchase additional securities from us;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- any agency fees or underwriting
discounts and other items constituting agents&#146; or underwriters&#146;
compensation;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- any initial public offering
price;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- any discounts or concessions allowed or
reallowed or paid to dealers; and</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>- any securities exchanges on which the
securities may be listed if it is other than the Nasdaq Capital
Market.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>8</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>Underwriters, dealers and agents that
participate in the distribution of the securities may be deemed to be
underwriters as defined in the Securities Act and any discounts or commissions
they receive from us and any profit on their resale of the securities may be
treated as underwriting discounts and commissions under the Securities Act. We
will identify in the applicable prospectus supplement any underwriters, dealers
or agents and will describe their compensation. We may have agreements with the
underwriters, dealers and agents to indemnify them against specified civil
liabilities, including liabilities under the Securities Act. Underwriters,
dealers and agents may engage in transactions with or perform services for us or
our subsidiaries in the ordinary course of their businesses. Certain persons
that participate in the distribution of the securities may engage in
transactions that stabilize, maintain or otherwise affect the price of the
securities, including over-allotment, stabilizing and short-covering
transactions in such securities, and the imposition of penalty bids, in
connection with an offering. Certain persons may also engage in passive market
making transactions as permitted by Rule 103 of Regulation M. Passive market
makers must comply with applicable volume and price limitations and must be
identified as passive market makers. In general, a passive market maker must
display its bid at a price not in excess of the highest independent bid for such
security; if all independent bids are lowered below the passive market maker&#146;s
bid, however, the passive market maker&#146;s bid must then be lowered when certain
purchase limits are exceeded.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>EXPERTS</FONT><FONT face="Times New Roman">
</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The financial statements and schedule of
Research Frontiers as of December 31, 2010 and 2009, and for each of the three
years in the period ended December 31, 2010, and management&#146;s assessment of the
effectiveness over internal controls as of December 31, 2010, incorporated by
reference into this prospectus have been so incorporated in reliance upon the
reports of BDO USA, LLP, an independent registered public accounting firm,
incorporated herein by reference, given on the authority of said firm as experts
in accounting and auditing.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>LEGAL MATTERS</FONT><FONT face="Times New Roman">
</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The legality of the securities offered
hereby has been passed upon by the law firm of Duane Morris LLP. As of the
January 19, 2012, Victor F. Keen, a Director of the Company and Of Counsel to
Duane Morris LLP owns 293,639 shares of the Company&#146;s Common Stock directly,
48,160 shares of Common Stock in his IRA, and holds options and warrants to
purchase 67,500 shares of the Company&#146;s Common Stock. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>9</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR><BR>
<P align=center><B><FONT face="Times New Roman" size=5>Research Frontiers Incorporated
</FONT></B></P>
<P align=center><B><FONT face="Times New Roman">1,900,000 Shares of Common Stock<br>Warrants to Purchase 380,000 Shares of
Common Stock </FONT></B><FONT face="Times New Roman"></FONT></P>
<P align=center>&nbsp;</P>
<P align=center><FONT face="Times New Roman" size=2>___________________<BR>&nbsp;<BR></FONT><B><FONT face="Times New Roman">Prospectus
Supplement<BR></FONT></B><FONT face="Times New Roman" size=2>___________________</FONT></P>
<P align=center>&nbsp;</P>
<P align=center><I><FONT face="Times New Roman" size=2>Sole Book-Running Manager
</FONT></I></P>
<P align=center><B><FONT face="Times New Roman" size=4>Craig-Hallum Capital
Group<BR></FONT></B><FONT face="Times New Roman" size=2>___________________ </FONT></P><br>
<P align=center><FONT face="Times New Roman">August 28, 2012</FONT></P><BR>
<HR align=center width="100%" noShade SIZE=2>



</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>rfi_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rfi_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@```````````````0``]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____X0",17AI9@``34T`
M*@````@`!0$2``,````!``$```$:``4````!````2@$;``4````!````4@$H
M``,````!``(``(=I``0````!````6@````````!(`````0```$@````!``.@
M`0`#`````0`!``"@`@`$`````0```B"@`P`$`````0```(``````_]L`0P`"
M`0$"`0$"`@$"`@("`@,%`P,#`P,&!`0#!0<&!P<'!@8&!P@+"0<("@@&!@D-
M"0H+"PP,#`<)#0X-#`X+#`P+_]L`0P$"`@(#`@,%`P,%"P@&"`L+"PL+"PL+
M"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+"PL+_\``
M$0@`@`(@`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'
M"`D*"__$`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R
M@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*
M4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2E
MIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S
M]/7V]_CY^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41
M``(!`@0$`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC
M,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:
M8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:
M``P#`0`"$0,1`#\`_<OXP_$FT^$WPF\4^+=;3?9>%](O-5N%_P"F=O%)(_\`
MZ+K^<2RUCQ'XJNM<GU;Q'?1?V#I\E[<3QW$G[WR_^VG_`"TK]O?^"R/Q2_X5
MQ^P)XO-O)^_UZ2WT:./_`)^8Y+B/[1'_`.`T=S7X3:1-J4/A+5+&Q@C^Q^(_
M+T[SY/\`6^9')YGEQ5YV,/TO@;#.EA,1C#Z6G_X)T_$R']AW3OCC_P`)A'_9
M&H:?'J,FE/>7$=S%;R2>7&/^><G_`"R_[^5Y;\"/VO\`XA?LR26_C3X6>)M;
MMKCPYJEO]LTV2\D^PZS;R>9YD=S%_JY/]5_K?]9^\_Z9QUN_%W_@H1\4_BM\
M#K#X8:U/;Z3X0\,Z9;Z=_9NG0FWEDM[>/RX_,S^\D_=Q#@5ZC^P?_P`$F_&/
M[7FA^&-=\4"QTKX4W]VFK7]]]LCDN=?CC\R/[-;1Q2?NO^6D4GF>7_Y#I+][
M4_=GIYU5J87**D,TJ0GB/^79^CW_``5^^,G_``KO_@FYXSU30;J2VN?$]O9Z
M3:%/W<LL5Y<11R1C_MWDN*_#_P#M+Q!_P@=YKG]N:M^ZO+?3K>".XD\VZDDK
M]./^#COXC)H_PM^%?@BS)C-]JUYKO[OC]W9VWV?R_P#KG_Q,_P#R'7YM?"WP
M7XW\?^.O"'@_X765QJ.MZG>?V_H%C!Y?F2W%MYG[W][_`->TO^L_YYT\2OWA
MAPE3J83**F(IU*=.I/\`G/O*+_@@/\4Y8XWE^+6G&0IB0QI=_P"->U_L=_\`
M!)#Q;^S[^T_X0\=?$7XA6_B#2_!NEW%M'ID?VC,EQ+'*/-_>'R_^7F7\HZ\:
M\'P?\%#)_%&EQ^)'\1QZ?]IC^T2?\2;_`%?F?O*^P/\`@FC:_':?P_X\U#]N
MRYU*/4+GQ`\>@6-V+/%KI\<?$D9MO^>ADZ2<_NQ6E/V?.?.<1XW'NA3IXC$P
MJ?X#Y,_X+H_MO^-?"/CW3_AC\,]5OM`T]K".^U.>TG,,M\).D7F1_P#+.OB;
MX'_L=^+?V@_&?Q'TWX9WUE+>?#K1_P"V=4\^>6.2_P#^F=M'_P`M/^6O[W_X
MY7ZB?\%6/^"6-_\`MG:A:>,/A!?6-GXSTRT^SO:7OR6VIQ_\LQYF/W4@]:_+
MOQ=X+^+O[#'Q/T^[^(>E>*/!7B.P_=6>IV\DEM++'_SRCOHOW=S'_P!,OWD=
M955>I[Y]5D&*53+*>'RRI"GB/MW^V7/@?XT^+W[/#R^(O@Q!XI\/^)]'>.\C
MCCL[D6WB./S(_,MKFV_U=S_ST_YZ5^YF@?'M-0_8_3XH:MI4VDR-X2_X2:XT
MRZ/ER6DGV/[1);R>\>?+_"O@7]AW_@MOXB'BWPOX9_:K@LM:TCQ1>1Z59^*[
M2W^S7-C>?\\KZVC_`'<G^MB_>Q>5_P!<_P#GG]5_\%B_B@?AE^P5XOC@D$5Y
MKWD:7;X_OR2>9)_Y#CEK:E^[IGQ6<PJ8[,U3JX?DJ71^&]YXVU_Q+<ZYJ,_B
M#5_+M8Y-1DDDN)/WO[S_`.VQ5]J_LY?\$;OB;^T-\"/"?CB+XF6^AVWBVPCU
M&WL9_M$DD,<G^K_\AXDKX2L]!U'4M&C@L8));?7KR/2HXX_^7JX\R.2./_OY
MY5??OA#P?_P4'^'_`(2TK0_"%KKMEH^CV<=G96B?V-Y5K;Q1^7''_P!^ZY:1
M^DYS5Q=&2I83$0A_C/6_A]_P1#\<>&]3\$)XI^)]E?:7H'BB#7M3@1+CS+^W
MB\K_`$:(_P#7..7_`+^5^ES#R(?,%?$O[`>G_M03?M,>*+C]L*[U:+P)8:''
M;:7#.;+R[V__`-&S+_HW[S_EE<_]_*T/^"Q_[:Z_LU_L[7&@>%I_+\4>,(Y+
M*W/_`#[6^/WDG_M/_OOTKMI\E*'M#\GQ%/%YUCU2;]I4/S]_X*F?MH:Q^US^
MTU>:/\'KZ^_X1CPI');VGV2X\N*Z\O\`UEQ_G_IG7B'P;^.&J?#^]\">*;G6
M-1,7@GQYI^HW(DO).;>3RY)/-_Z9_P"C5!\*[/R-4T?3;+6=$LM8\4>9J.J7
M^I:A';16NGV_[S[-YLO_`"TN?*_U?_7..N+L[/[;\.?'&E?ZV2*SCO8_^W>Y
MC_\`:<LM>3[2I[3VA^MXS#4%E&(R^A]B!_3WY7[W-?C-_P`%]/CA?:A^UIIG
MACPW?7$=EX8T2WC?[//Y7E7DDDDDL?\`X#RV1K]4?V4_B-_PN']F;X;^*KEU
MEE\1^&]/U*0_]-)+>.23_P`B$U^$7[>/CFZ^-_[>/C_5-*M_MMQ=>)+C3H(X
M_P#52I9R_8[?R_\`KK;VT=>KC)_NS\ZX'P_UG,O:?\^S=_9._8V\?_M>_'?Q
M!X$\`^+)M.O/#FAQZK>7U]<7'V;S)/+\NW_=_P#+3][_`.0I*X_Q;:^./V;/
MCU/X0\;Z_?R7FCW\FGW#V.IRB/\`UGE^9;2'][%_UTJY^SC^WI\1?V7]=\<:
M_P#!=])LM4^(,D<=Y?SZ?]IEM?L_F^7':^9^[_Y:_P#+3S/]72_L^?`'QW^U
M-\?+B'P[:CQ'XODC_P"$CDM+O5(XI+KS)/,^TRRRR_O(_,E_>>7YDE>?I[/V
M?_+P_1)8C$4_:U\?4A]7^P?J/_P15_:;\8?'WX'^+_#_`,;]5NM?UCX:^()=
M%35KAS]HO[<8\OS3_P`M)/\`6?O._P"[KYK_`."JO_!5#Q=JWQ8U#X6?LMZM
M=:?9Z9<_V=J>HV,GEWU[=_\`+2**7_EG'_RSS'SDFOL3]BC]D.?_`()V?L:>
M)X=6U:+5O&6JF[\0ZYJ*QXBDO?L_^KC_`.F<?EC_`,B5^*'P]UB?[?XL\53R
M>;J&EZ7>7L<G_3Q)^[\S_P`BUTXRI4I4TCXGA'+L)7JXG,*]/]W3/3_V=_V#
M?B+^V'XC\2/\+;_^UKCP[YG]L:M/)_HWVSR_,^SQ7/\`RUN.?^N?_32N(^%G
MQ-\:?`_Q%JDWPMU_4?"?C/PYYES;W=C<>7]J^S_ZRVN8O]7<Q^7_`,]*_:S_
M`())_!_3_@;_`,$[_AI:::D4;:_I$?B.^GP`9I+T?:=\ASU\N2./_MG7NL/@
M+PKJ.Q+72M!F,C_:$_T2.3]Y_P`]*I8/KSF>*XOJ9A0JT\72]HO^7?\`</-?
MV*OVL;']J']C3PU\3]32WTW[?ITLFJ(G^JMKBWDDCN/^`>9%+7X@:O\`&77/
M'G[3_B#Q-JNHZEY=K>7FJW&^\D_Y=XY)/_:5?MU_P44^(%M\)/V,/'6HL`J#
M3/L4:)V^T8M_W?OLDDK^?'&HZ;X7U363)Y>GR_\`$NO)/,_UOF?\L_\`R%4X
MW]Y:F>AP%AE3P^)QE0_5G]B'4K[]GW_@A3KGC'Q%=7/]I^+(]0U"YN)Y/,EB
M^T7']G1R_P#?N**2OS.T?XA:YIOPJ\>:Y/K.I?:);>/3HY/MDG^LN)/WG_D.
M*6O8OVE?!?[3/[-?P)TCPC^T7/J^B>`+FW^S:9I,FIV=S%Y<?E_N_+MI))/^
M6E<A^S9\,Q\4O'_P8\$,GF1>-O'<=S>I_P!.=M)'')_Y#\VLL3^]J4Z9Z%#+
MJ>393B:WM(3]I_(?O+^R5\,[CX-_LS>`/"VL>8+[0?#]G97?F',GV@6\?F'_
M`+^>97IAY%`Z4'I7K'Y*SY,_X+*_%I_A+^P/XL_LJ<1:CKUQ9Z3:#_GJ)+F.
M2XC_`/`:*YK\/K.;Q'>>$H]1L=8U>2XNM4M])L[2.XD\VZN)*_3'_@XW^(SV
M?@;X:>"[=QY>IWEYK,GE_P"L\RWCCMX_^V?EWUS_`-^Z_.;X2^%O'_BGX@>!
M]`^#VE7&I>)(KS_A(_#]I!;QR2RR6_[S[3Y4O^M_X]O^6G_/.O.Q'\2Q^L<)
M8>IA,HJ8BG5IPG/^<^[1_P`&_P#\4V^Y\7=/(_ZYW%?3?_!/'_@F]XB_9"^/
M?C#QK\1_&%OXH&O:7;Z3IT,/VC_08X_*\SS/,/\`T[15\Q^!/BE_P4"G\3P#
MQA#XH&G1^9+(CZ#I0\W9'_J_^/;N:^JO@?\`%_XO_"#_`()>^)_B%^V/=7$W
MQ+TO2-7U9+>\M+:VDM_*\S[';&.VCCCS)Y41_P"V@YK>G[/G/F.(L3CZSIX?
M$8B%3_`?DS^T%\3-8_:._;1\9W7AO7+VVLO$7B34)+.?[1)_QY^9)]GD\K_K
MV\JNN_9X_8-^)O[3/[)NO_%?P#XLM[;2]"N;R+[#?7EQ')?6]O'')))'+_J_
M^>O_`'[KYY\*ZE=>#_[0U+PXD7V>UMY++SY_^76.3]W_`-_*];\-_MP_%;X>
M_LS6?P-\'75MI/AB+S(I$M+/_3K^.XDEN9(Y9?\`EKYGF_\`+/\`UD=<=.I_
MS\/T?$4,=2IX;"9?4A[D/WAQGP]^-GCOX62:Q??#KQCK^@:YH,?VVWN[#4)(
M_P!Y')^\CE_Y9RQ^7YO[J2OW6^"G[9>FZM_P3\\/?&CXT.FGVB^&(]9U?R8_
M^6D<7[PQ1_\`323_`%<?_32.OQO_`&*?^">OQ!_;BTZ[;X3?V=8^&+N\.E:Q
MXAN[N/&EQQ212211VW_'Q)<_ZK_EG%'_`--/WE?=/_!9_2[7]F7_`()N?#KX
M:?#LW"Z0-7L-%D0CFYL[.SED\R3_`*:?:(K:3_KIBNG#>TI4_P!X?`Y\L+G.
M;TL/0^WN?#O[7?\`P4(^)G[;/C'6)-<URY\.>!+:,RQZ':WDD>FV%O\`]/7E
M?\?,G0?O?^6@_=QQ_P"KK'\(_P#!,[XE^*?V6;KXL>'=#@M_"")]HMX)P;>]
MOK/K)>QVW:W^LO\`TT_U=<S\%?A;;_%?QC\*/`NH2>5IWQ*\9V]GJDD?^M^S
MQR6T?E_^3,M?O/\`M5:_H_P@_9"\;R36]K9:5HWARXL[6`IY<9_T<QV]O'CU
M<Q1UEAZ?M?WE0]+,\^J9!C%EN`I_NX?^3GX6?LI_ME^/OV0=3_X2;X(:Q<QV
M^@R1W.J>'I)/^)9K-GYOER>;%_JXI/WL7[V/]Y^\K]]/`OQQT?QW^S]I_P`2
M=*DE/AW5-$37H_,'[V*W-OYO_?=?S@?VE'-I?C34O]7;RZ?)^[_ZZ21QQQU^
MO>I^)+S]G+_@@KHPU0A=4U#P3:6<=N3^]'V_'[L?]-!;W,G_`'[K3#U/<J'#
MQ=E].GF5*$/^7EC\H/%7QR\3ZQ\4-0\1SZK?17DNH27OE_;)/*\SS/,KZG_8
M+_;A?]G;X$_M!^`?$>JW/V34_#\GB/P?<3W'^JDN(X[;R_-_[:VW_@-+7RQX
M/T&QF^%6J2:JG^F:IJ%OIVER?]/'ER2?^1/]7_VUKF[P0:QX7T^>>3_3-&DD
MMO\`KK;R?O/_`"')YO\`W\KBIXCV4S[O.\FH9K3I4Z>].</_```Z#3?'FOV?
MPO\`%E]!JNK2W$MO;Z3;_P"D2?ZRXD_^-Q2U^V_[0/[#OBOXI_L#>#/A1\.?
M$]OH6J:#::9;7E_,))!=QV]OY<G^K_YZ2?O*_(S]CKX5_P#"VOCY\"_!TT?F
MIXC\:?VM>1_\];.S\N23_P`AQ7-?T1.VT<5VX."J4[GYWQIF'LLVYZ7V#^>_
M]O?]E7Q5^P=X\T'PYXJ\=S:_J&N6$FH2?89+B/[#'YGEQ^9YG_/3_2?^_58?
M[,_P$\8?M/?M">%/A]X6\57UE=^(M+DU:XNYIY#'81QQR2?O/^_<7_?VO2?^
M"V?Q'G^*?_!2'Q1IT#^8GA+3]/\`#EGL_P!4?]&^V_\`?SS+Z6/_`+9U[O\`
M\$'/A\/$O[<7Q@\60G_1/!.AV?A2W'?$DO\`][9/^_M9\B]O[,^HS#/\7@,D
MP]>_[R9[W^QS_P`$IO%7[/\`^T]X0\=^./'%OK.F>$=!DTV"P3SSYEY)')')
M<?O/7S9/SK\R?CK\8]5^/?[=/C/5[?5=2_L[7?%]P+?R[B012Z?'<>7;R?\`
M@-%%7[P?M8?%E_@3^S+X_P#&%L\4<_ACP_J&JP&0<&2*WDDC'_?P1U_.9\*_
M^*5TO6-1\R67^P=#N/+DD_YZ21_9H_\`T;3QG[J'LX'F<%59UJ^-Q^(?V#]<
M/^#?O2+OQ'\!_B1\0];N+RXN/&/B^XC@^T2>8?L]O'^[_P#(ES+7YK?'#XI:
MQ\>_VH_&>IV'B"^CLM8U/4-1CD2XD\JUM_WDG[K_`*9^77ZH_LUVB?LD_P#!
M$'2[J;%C=KX(N-520_\`/SJ'F2Q^9_VTNHZ_%^SFU&'1M<UBQ_=V<5O]FU"3
M]W_J[C]WY?\`VT_Z9TL8]%3IFW!%/7&XV9]=?L/?\$NOB1^VW^S]9?$+1/'_
M`/8%AJ%Y<V]O;W<EQ)++Y4GE^;^[_P"FGF?]^Z]SB_X(/?$G_A76LZ-!\7-/
MBN-8GM_](\N\_=1Q_O,?ZVO*/V>?`O[<GPU^"WA_1/V?]/UW3_!<5N;C2[6W
M_LHQ11SG[1_RT_>?O#+YG[S_`)Z5]1_LA:;^UW>?M2>`$_:*FU6#P#::5<77
MB22;^S?+NKR2*7R[?]W^\_=R?9O]7_SSK54J?/\`PSASO'9E3HU.?&0FO[AT
M_P#P6X\=#X&?\$_;/0/#<T]M_;VL6&BV\X?]["EO')>I^9L8X_\`MI7Y#^#]
M!\5>-I/"=KH>NZE)J'C+Q);^'-/@^T2?ZR3RX_,_[^2Q5][?\'&WQ-^V^./A
MYX.L92?L&F7&JWD>?];]HECCM_\`TANA_P!M*^$/AW\1?$WPC\<^!=:T72].
MDO\`P`_]NZ?!=(7CE\S]Y]IDC$N1'_JJQQ%3]^>WPQ0Q&$R'VF$_B5)GJ_[=
MG[#_`,0OV#KK1'\?^,+?7K37#(()[6XN./+&?WL<GUKV/_@CS^V%XTT3]M#P
MG\.=;U_5M;\*?$O1[RXCL+^\DN8M&N[>.YE\RV\W_5?\>,O[K_IK_P!,Z^7?
MVC?VJ_B%^VI\0-+U3XSZK%</=7$>G:?'!']FL;63_GG_`,\XO];_`*V23_MI
M7Z,?\$J/^"57BKX&?&J/XI?M(V]GI.JZ/I<FD^&_#UO/'<R6$<G^LN+J6+]W
MYA\R;]W'Q_I$E5AN?VESBXOQ$:67T\/C>2>(-7_@N=^V1XM_9[\'>'_"7P?U
M"YT.\\5I+<7>I6DGE7,5O'_!%)_RS/O7YI?`_P#9?\3?M5_M#:/X$\'ZQ92^
M)->TB37I+O4I_+B\OR_,\OS/WDDDE?L/_P`%/_\`@G4/VZO`NFR>&-0MM(\5
M>'/,_L^>?_CWD23K'*/2OR(^-?[-?QA_8I\4Z?/\6?#NM:*=*N/,TO6;>23R
MXI/^G:^MO]5_UR\S_MG2Q//[3WS3A;%)8#V&$G"&(\QGP?TWXH?#'XA7$'@?
M_A+=`\26OF1Z?JUA')%+%<1_ZN.67_EK')_J_*D_=_O*_;[_`()^_'K7/VE_
MV3?"'BWXI:%<>'_$FJV\D>J6DEL]L/M$4LD3R1QR?\LY/+\P?]=*_.+]E+_@
MN1XW^%C:>?VD?^*Y\#Q7$=EJ&I"WCBUS1O,_U<O[K]W?1_\`;.*3_P!J?KUH
MVO6FO:7;WVDSQ7-I>11W$$D?*2QR<QO^-:X;_IV?)\5XBK5Q7^TX?DJ&STHH
MHKM/EPHHHH`_+_\`X.-?B.;/P-\-/"438CO[^[UIRG7S+>..WC'_`&TCOKG_
M`+]U\5?L+_"S_A9G[8_[._A+R/,C_MB3Q7>1_P#3.WD\S][_`-L['_R+7ZB?
M%O\`;%\`ZYXOO;/XL_L]_%_Q1J&EW,FG"[E^&$FI1?NW?_57'[R.2/.3YD9,
M?/6J7AO]M7X7^"M4CU3PG^S7\:M)U6VB^SP7<'PDEM[B./\`YYQR1Q]/;-<[
MH^_[3VA]E0Q^*H94\OIT/CZGP'_P6._9K?\`9>_;`?Q!X&A2WT?Q1_Q-;-$C
M_=QR?\M(_P#T;^[_`.>=>O\`_!!G]IB/P!\<]?\`@]JLTD?ASQA;_P#"4>$X
MY)?,^S7&#]HMH_\`MG')_P"`TG_/2OJKQM^WO\/?B6MN/B+^SI\=M=$/^K&H
M_"RXN/*_[^BLS2_VR?A3H6I6=[X5_9C^,&FZCIG_`!YWEK\()(Y+7_KE)Y?[
MNE3H^SG?G%F6-Q&:X##X:IA_WE/[9\0_\%^OB:_C;]NZ/1-.D\VR\'^&[.S=
M/^>5Y)))<R?^0Y;'_OW7D_[#?[7OA[]E3]KJ#XB>+="U/6+'1_#?]BZ7;6[Q
MQRPW'EQ1R22?^3/_`']K]+_$'[6WPI\8:Y>ZKXR_9D^,6LZI?^7)>7=U\();
MBYN?W0C_`'DLD?[S]W%''_VSJ&+]I[X)@\_LG_%<?7X.G_XW3]C[_M/:';0S
M*/U"GE^(PG/R>9RW@;_@X(\(^.?%5GI>G^`/$UM)=[\N]S;_`+K]UYGK7TC^
MR3^U-:_\%"?V8=4\4^%-*U7PE8:T]WI5D9Y(Y9B!'Y?VB,Q_]-#)_P!^S7CE
MK^UC\'--NP^E?LL_%B*3_5[T^#LD7_M.NJ\(?\%&?!_P\T*WTOP1\`_V@-$T
MRV&([6Q^&-Q;6T7TCCZ4Z=W_`!#P<PP\:CIO"83D^=S\H/CCXF^+O[./Q9\1
M^'?C!K/C6W>:.XMW1]8N/*CCD_Y:Q2UU?Q._X*7ZM\6OV$/#?P8\2:#'J6IZ
M-/'%)X@N[CS9;JWC_P!7^Z_Y97/[WRO]9)_J_P#II7Z4>.?^"@'@3XH:5]A^
M(/[//QYU^T[PZC\+;B]B_*0$5Q:?'WX!CS(V_9!^)9CD_P!9_P`65_\`M59?
M5?9_\O#Z59RISI5YX/\`>4^Q^;G[)'[,&O\`[4OQ9\%_#WP397%Q%%KD>O>*
M+](_W6@VD?3S)?\`GKY?F?NO^>OE5]V_\'&OQ3_L[X8?#SPA`!)_:NH7&K3I
M_P`\_L\?EQ_^E,A_[9U[/X8_X*)>!_A)X4%K\-_V>/V@-#TB'I8Z+\([R.,?
M2VMHJQ?'G_!2+X8?$R6*3XC?LP?M.>()(TV(]_\``C5;GRO^_MO6D*?[OV<#
MQ<1GDXYM3S#%4_\`MP_(WX'_`!9T?X<?%WX6:WXPTZ^U'1_`FN?V]>6MO)Y<
MM]<1R1R1_P#HJV_\B5^F]K_P<7^"M3NXH+?X;>*)))9/+C_T^WYK?/[;?P,)
MX_8]_:"Q_P!F\ZC_`/(U$/[;7P/LY8Y(/V0/VB?,C_U;_P##/NH\?^2U*G2G
M2^`Z<=GV4YC6G7KX:?/_`(SU[]E/_@IAX<_:DOOB>]MH^I>'-)^%?E_VG?7\
M\<D,QD\TDQX_YY_9I:_(_P#:X_:#N_VZ?VJ-?\4^*IY++POI<<DD?_+3[!I\
M?_/+_II_[4DK]*M(_P""CGPO\.6-_9:'^R]^TQ8V6LOYFH06_P`!=5CBOW_Z
M:Q_9_P!Y^-8T/[:WP1L8;F%/V2?VB)8+K_6(?V?=1,;_`(?9JBIAYU8:GG9+
MGU')JE3$*E^\^QY'SQ_P3\_X(IZ=^T_^S19^/_C=J_B/0#XCN)+G0["Q-N)/
M[/\`^6<DOF1?ZR3][_VS\NOCJ;X;R?#WX\>)/!4_F_\`'OJ&D_O/];_Q[2>7
M_P"1/*K]A-+_`."NWA71K&.TTW]GW]K>WL[:/9&B?!368XXD_N?ZJN0N_P!O
M/X.ZCKLFJ:A^R=^T9<ZG))YCWC_`#49)I9/^>AE^S?K2KX+VEN0]'!<:8BE[
M6&+]_P!H:'_!*[]H&T\+?\$:]+\9:MY=S_PKG1]8DO(Q_P`\[.2YN(X_^_7E
M5^0WPQO)]-\4:QKE]=?:;CPYH]Q<^?\`\]9(X_+C_P#1M?KUI'_!2#X8:'X,
MN?#OAS]F#]IRR\/7QD^TZ3;_``)U6*RN?,^_YD7V;RZQK?\`;;^!]C;2I!^R
M)^T0D=U^[DC/[/FH_O/_`"6K7$8?ZS8\[)\_ADT,1:G[]0^?]8_X)^IJ_P#P
M0Z^'GB.RMF_X2OP[;3^)I!''^\N;.\N3+Y?_`&SC^RR?]LI/^>E?&WP(^->L
M_!O7?#_C?P#)+_PD?PPOX]1MXP<?;]/DD\NXMI?^F?[W_P`B25^N@_X*H>"(
M_"']AP_L[?M4QZ)Y/V/^S!\$=9^S?9_+\ORO*^S^7Y7E_P#+/IVKF(?VY_@A
M"9/)_9#_`&AX_-C\M\_L^ZC^]3_P&I5,-[2I[0UR_B#V6!J8/$4^?G_`^RO#
M/BO1/VA/@CI^L>%9A<Z!XRTB.YMWC_Y:P7$>1^DE?S[_`!U^"VM_L8_';Q)X
M3^)6CW)LI8[BR_YYQ:II\G^KDMI?^_=?K5X:_P""J_@KP1I$&E^#?V>?VJM(
MTRU_=P6MK\$-9MK:(?\`3...VXK+^(?_``4G^&_Q9TTV/Q3_`&8OVG/$E@GS
MQP:E\"-5O(O^_<EM3Q&']JC+AWB+^Q'4IU*?/3GT/SXTW_@J-XPL_P!A[3_@
M=X.AEN9+7_B6V^L^7Y=U+I__`"SMO*_>?O(^(_,_YY^7_P!M.4_9-_9`\8_M
MB^-M/\"?#'[48/MD=SXD\0#]Y;>&+./_`)912_\`/S)_SRC_`/CE??$7[1/[
M-\,#1P_L8?'P1_\`//\`X9]U3RY/P^S5Z5X._P""I?@?X?:1!I?@']G']J;0
M]+MA^XM;'X&ZS;6T7TCCMN*R6&_>>TF=N-XCP[PM3"8/#\D)G`_\%R/%EK\(
M?V,?"G@/PI)+:Q7,\=O!&[^8\UG9V_E^7]?](C_>?[%?G7^R_P##+_A:7Q3^
M!G@B>/S8_&/C>/4KR/\`Z<[>2/S/_(?VFOU"\;?\%+/AO\38X%^(W[,G[4.O
MI;%_(_M'X&:K<^5O_P">?FV]4]`_X*!_"7PYJ]I>^%_V6OVDM,U#2B\=G=0?
M`;58IK7S/O\`E21V^8_OFBKAO:U/:'-A<_AA\LJ9?"G\9\W_`/!PW\3CK/QC
M\(^%HG#VVCZ:;EL?\LIY)/WD?_?O[,?QKG?^"/?PR_X3;_@I%X6CGC'V?X8>
M")-1DS_S^7'[O_V^_P#(=?6/C'_@H'\)?'NJ?VCXP_95_:4UJ_D^_/=?`35;
MB63_`+:26U7?"?\`P4C^&?@74KB^\%?LQ?M-Z)?WL?EW%Q:?`G5;:6Y3_IK)
M';<T?5OWGM`KY_"IEE/+(4S[KH/0U\=?\/B]`_Z(-^U__P"&4UW_`.-4'_@L
M7H&/^2#?M?\`_AE-=_\`C5=I\P?GU_P7G^(__"=_MW7.C6$G[OPGHEAI4D'_
M`$\>7+>^9_W[OHO^_=>F?\$5/AD?$G_!1+Q7JLJ;[3X8>#+;1;>3_GE<7'E?
MX75?0_B;]OCX0>,-?EU7Q)^RI^TAJ>J7'^LNKGX`ZI+<2?\`;62VJWX*_P""
MEWPZ^']Y=W'P_P#V9_VH?#\^IB-[V2P^!FK6TMWY?W/-\JW_`'G^LDY[<US?
M5OW_`+0^FQF?PK993R^%/X#[G89%?%G_``77^)K_``__`&";_3H)OLMQXLUR
MPTJ*XS_JC'+]M(_[:1V,D?\`VTK2_P"'Q'A_/_)!OVO?_#+ZY_\`&JY[Q[_P
M4S^'OQ0M((/B+^S7^U%K\%M)YD$>H_`S5;F*)_\`GIB6WXK69X6#JPPM>G5F
MMC\=M!\'W?C;P;X?\*Z'_P`A3X@^++/2;?\`Z:^7^[_]&7,5?='_``7F_9)M
M?A;XD\,^-OA[:?9M-N;2/2KCR_\`ED]O'''%_P"0_+_*2OHC3?V\O@_H\MA-
MI/[)?[15M<Z9/]HLY(_@#J*26LG_`#TB/V;]W)]*Z7Q=_P`%1_`GCO2S8^/O
MV<?VI=<T\OY@@OO@?K-S'O\`^N<EM7-]67L^0^BJ<5U%FJQ].G\CX%_X)#_M
M3O\`L[?MK:&FJ77E^$/C3_Q)=4C_`.6=KK$?_'O)_P!_)/\`R=D_YYU^D'_!
M7[]D35?VO/V3Y['X=0&]\2>%-0CUZPL_^?\`\N*2.2#_`*Z>5<R21_\`36.*
MO,8?VYO@G9"/[/\`LB?M$1^7)]HCV?L^:C^ZD_YZ?\>U=X__``6%\/OU^`W[
M7OX_!?7/_C5=%*G^[]F>5B<RB\?]=PZY&?BEH/C;4OA[?:7_`,?ND^)/!NL?
MVMH]WY?[W2[R.2/S(Y8I?^FD47_7/RZ^A?VU?^"L/C?]MOP'I'ABXTNS\+Z1
M'%$^L6]C<>;%J<__`#TS)S''_P`\XC_VT\S]WY?W%\4/VQ_@3\;->_M#XL?L
MB?M#>(M4B_U>H7WP`U26Y'_;4VWF5CZ9^T;^SAH]]'=6?[%?QY^TQ?ZN1_V=
M]0D\K_R6KG^KSM[,^FJ<5X&K66+J8;]_^!\=_P#!.C_@FYK_`.VWXVT?^W;&
MYLOA/HUY'J7B#67CDBCUZ2/_`%=E8_\`/7_EIYDO_363_IGYOV1_P<(?$B/P
MA^S3X-\&Z24LX]<U.2YC2,>6#':1^7Y?E_\`//\`TF/_`+]UZE8_\%?/#&F1
M1P67[/W[7$%O$FQ$3X+ZS''$G_?JL3QS_P`%)OAG\3Q'_P`+'_9C_:=U][7F
MW_M'X$:K<F+_`*Y^9;5K]7_=^S/!AG]2KF5/,,6N>Q^:?[&_P:@^,G[3'[/G
M@#5(!<VFJ:Q<>)]3@D_U4L%O^\_]%VTG_?VN,_;6^`5U^S-^TSXK\)WOF^58
MWDDMO))'_K;>3_5R5^JOA?\`X*%?"OP?K,&J^%?V7?VD],U.TM_LT%W:_`75
M([F*/_GG'+';<1^U+XV_X*%_"?XAZK]N\??LL_M*:W>XV>?=?`75;B3_`+^2
M6U94\$N2Q[>"XU>%Q^(Q?L_W<^A\H_\`!%+X6?\`"4_\%#;>^N$Q;_##P'YG
M_7*\O?+_`/:=S<_]^Z_9G;@MGTKX<\'?\%)_AM\/KV[N?`'[,?[4.B7=_L^V
MW%C\#-5MI;KR_P#5^88[?]Y723?\%@O#LT3I/\!?VNY$DX9?^%*:Y_\`&N*Z
M,/3]E#D/D\RQO]H8N>)?VS\=M1^(4'QW_:Y\0>.)Y/M6GZ]XDU#Q/'_TRL_M
M,E[''_W[\J.OU%_X-U_AS)H/[&.O>+=6CQ?^._$]W?>:?^6L$?EQ_P#HT7-2
M67[;?P-TV'98?L?_`+05NGE^7LC_`&>-10>7_P`\_P#CVKJ?"O\`P5-\$>#-
M#M])\'?L[_M5:+I5L?W%I:_`_6;>VC^??^[BCM\#]*BGAO9U/:'JYUG\<UI8
M?#4Z?)"F._X+V_$X>!/^">VIZ3YXM[GQKKFGZ-;R>FR7[;)_Y"L9:_&OPKX5
MNO&'@B/P_H?_`"$/'GB33_#EO_W\_P#CDMM7[$^//^"FOPY^*%LEK\3/V;/V
MH?$,%K+Y\$>H_`W5;F*&3[GF1B2WX.#6+I?[=7P:T:>TGTK]D_\`:,M[C3)_
MMMG)'\`=122UN/\`GI$?LW[N3WI5,/[6I<URW/X9=@,1@U3]^?4T/^"WWB:U
M^#?_``3^M?"_A_"6^LW]IHT<)'/V>WC\P?E);6X_&OQPTW7M-_X0B/0]<@N9
M;>ZURWO=4\O_`):V<?\`RSB_Z:?ZVOV=\;_\%-?AU\3K6.#XC?LU?M0Z_;Q_
MO$34O@7JMS%%]/-MJY=?VT_@6A_Y-`_:$/U_9YU'_P"1J*F&]K4]H=.2<24<
MMP-7!UZ7/SG+VW_!QMX(L;6-(OAOXGCCC38D<=W;_N_UKWO]D_\`X*D:-^UQ
M^T#<?#[PKX0US3;FQT#^WKN^GN(Y(K5/W6(^/^6G^DQ5YBW[;WP//_-GG[0/
MU_X9YU'_`.1JVO"W_!2#X9^#=2GOO"'[,?[3&BZA?1A)[JQ^!&JV\LJ=HY9(
M[;)K7W^<\C,,3@*U.V'P_)/_`!GY^_\`!8;XA2?%_P#X*'^*[2S<7$>C26>@
MZ<X_YY1QQ^9'_P!L[V6^KV__`()(_LX:7^T5\8_VA[KQ/;DZ1:Z);^![-WC\
MSRO,_P!9Y?\`USDL8I/QKW[4?V\/@]J6LOJ.K?LF?M&7-^UQ]IDNW^`6HR32
MR;_,\PR?9L^9YG.<]:W?!7_!3?X<_#I;I/AQ^S5^U#X?2_D\^XCT[X$:M;"Z
MD_YZ2>5;_O#[US?5KU/:'?B^(75P&'P="')[,_(+XC?">Z^%WQ>\3_#WQ["+
M<&\DTYR__+M)YG[N7_MG)_Y#\ROV0_X(I_M83_M-_L>V=CXUF>3QG\/YSX<U
MCS_];*D?_'O+)_VS_=_]=(I*Y;Q;^W[\(?&>KOJ7C']E+]I#5M0E_P!9/=?`
M'5;B63_MI);5>\%?\%*/AMX!OKN;P%^S'^TWH$FIGS+R2Q^!.JVTEUSQYICM
MOWG^LDK7#TO9&.?9]#.53FZ?[Q'YQ?M96GQ-_8O_`&P=?T[QCJ/B@6\6J7%S
MI;OJ$D<6L:7))^[D\W_KG_K/^FGF5I?#G_@J!JW@O]B3Q-\&_%.D2>,7U>>7
M^S]9U:[\V6VMY?WDD<L<O^LDCD_U<GF?\M!_SRK]#OB'_P`%+OAU\6M#?2OB
MG^S/^U!XETL_/]DU+X$ZK>6V?^N<MMS7&V7[2_[.>F0[-)_8L^.-NG]R/]G"
M]C'_`*14/#_R'HT>)\+.G2]OAOWE/J?F#\+/@?XF^-4D?PZ^%NER:CXK\>7E
MO%':)'_QX6<<GF27-S_SRC_U7_;/S*_HL^%7@6/X:_"_PUX:L9_/C\.:7;:4
MDA'^N^SQ1Q;S_P!^Z^0OAQ_P4B^&'P?TZ>U^$?[+_P"T[X7MY/WCP:7\!]5L
MHI?J(K85T@_X+$>'Q_S07]K[_P`,OKG_`,:J\/2]DCPL^SJIG6*^L5#[&'2B
MOCK_`(?%Z!_T0;]K_P#\,IKO_P`:K+\4_P#!;KP1X#T<ZAXW^#W[56B:?%]^
MXO\`X0:S;1?C))%6IY)]LT5^94W_``=?_LCVVL'3;R_^)$5_O\LVC^%+CS?,
M_P">?EU]-_L1_P#!3GP-^WGXGO--^#7ACXI6%M96!U$:EK_@^[TK3)H_,2/R
MX[J7]W))F0_NQS^ZD/1*`/HS[3&>J1?]]"F%[<_>\K_OH5\X>,?^"4'[/_CC
MQ3J.O>,?!'VG5=7NY-0O)_[=U"(2RR2>9(YCCN/+_2J3?\$=_P!FH'_D01_X
M4&H?_)-3[YZM/#8-+6O4_P#`(_\`R9].F[MSU,/YBC[7;#O#^8KYA_X<W_LV
M_P#0A_\`EP:A_P#)-'_#F_\`9M_Z$/\`\N#4/_DFE[YK]6P'_/\`J?\`@N/_
M`,F?4'VVW]8?^^A3?M=OZP_F*^8?^'-_[-O_`$(?_EP:A_\`)-'_``YO_9M_
MZ$/_`,N#4/\`Y)H]\/JV`_Y_U/\`P7'_`.3/I[[7;^L/YBC[7;^L/YBOF'_A
MS?\`LV_]"'_Y<&H?_)-'_#G#]FSOX#_\N#4/_DFCWP^K8#_G_4_\%Q_^3/I_
M[1;>L-!N+8<YAKY?_P"'-W[-G_0C_P#E?U#_`.2:/^'-W[-A_P"9'_\`*_J'
M_P`DT>_W)^KX#_G]4_\``/\`[<^GM,U2+42?LV?SJYNXS7A/[/'[`7PH_9;\
M:7&N_`WPTFBZO=63:=)<#5+RY+VYDCD>/R[B61!^\CCZ#/O7NP(QD<UHUV/-
MQ4*=.?[KX/,E'(HHHI&(8HQBBB@`HHHH`,8HHHH`",]:",]:**`#%%%%`!C-
M%%%`!01GK110`4$9ZT44`%%%%`!1CFBB@`Q1110`4$9ZT44`%%%%`!BBBB@`
MHHHH`,48HHH`*.M%%`!1152^O?LD3R2[]D:;_D3?0!\?_%'_`(+A_LT?"3Q]
MK/AWQ3\0[A7\.:B^E:YJMKX<U6\TC1KQ)/+>WN=1BMI+>-_,S'_K/W>1S7>?
MM"_\%2?@C^RMXI\-Z)\9/&-]'JGC'3#K.C6^C^&]5UW^T+,?\O$7]G6UP/+_
M`'D?/3FO@3X#_#SXE?#7]AWQAXE_X)D_$'X1_&_]E3Q&FMZJ_@GX@Z/<:5J=
MC922W$FHZ<-1B_Y:9-S_`,?L8_UG/K69X?\`CKXT^*7[97[(OC7_`()O_#GP
M1ILFL?L^7AT_PWXHU2XLK'1M/CO;*/[/'<6T4DDGE>5%''^[_>1T`??7@[_@
MKW^SW\1?@]\0_'7A?XCQMX?^&%OYWBOSM&U"WOM"C<X2273I+9+PCZ1^N*QO
MAO\`\%L?V9_B/X^\/^%-%^(UWIVM^)I([;2X-=\+ZSHJ7\C_`.K2.YU&RCCD
MDZ?\M*^(/^"@'['/Q9\/_LG_`+8G[0G[=TW@/3_&?C;X<6GA73/#W@@7%S8V
M&GV]S')YMU<W,4<EQ<F01\XQ'&/IY?T'_P`%WO\`A$3_`,$,_%D?CZ.U>_DT
MS3(_"Z%`;[^V/-M_L?V(#]Y]H_ZY_P#+/S?^6>:`/T8Z5\6W7_!>[]EBU\>2
M:%-\2;C[%%J']E2>)/\`A'M1_P"$9BO/,\KRO[7^S?9OO_\`+7S?*_Z:59M/
MVY?%'A_Q1+X(^/?P$^+-KH>EZ1)'XC\<V]I;/X=V1Z?YMS<Q&*Y^TRQDQR11
M^7'YGM7Q+IGPT^*W[,O_``2JO-4_9D\8_!3]IK]C&+PY=ZU'X7\8Z?<Z+KD>
MAC?<2645[;?NY;B/,F3<11R>9'_JQ)^[H`_9^&42^E25^0FA6GB'_@H3^U_\
M0[3X?_%KXV?"KX6:%\%O"OB[PYX?\,>))=%EL+C4+*:6WDD,?[S$<<9\R/I)
M)Y?F?ZL5SO[)GQ*^*VB>$_V%/C7XK^.'Q.\6:]\==?'AWQ7HVKZOYOAZZM)+
M.]\ORM-BCCCBEB^S1'S4_>22?ZR@#]G:P/%GBS3?!GA^_P!7\67=MINF:9;R
M7EW>3R>7%;01Q^9)))(?]6@`Y^E?A#XR_:T^*=Q\//#'QY^#GCS]JCQ-I]]\
M2]/MQX\UC6[3PYX"UZSN-6-L+.R\+?;9))+?RP\?F>5YF8S))Y?^K'M_Q$^#
MGC+]JZX_;U\2_%;X[_&FR\/?"?5=?TCPYX5T/Q1)8Z&+?^P/M$D=]%C_`$F,
MF6+]UQY?ER?\])*`/L3XM_\`!5/1?AO>:G?Z)X%\1^*O"EC\-;CXN6>NZ7?V
M7V;5?#]O''*;B**:2.3S#YL>R.3K72?L[_\`!3/P+^T_\;O!?@SX:66N2W_C
M?X:CXI174\<8M=/L_M5M;?8KG$G_`!^1R70\R+_EGCGJE>-_\$]O^">W@CXM
M_P#!,[X07'CW4_&^HW7C3]GVT\$7[S:IYHATS6+*VN;B.V,D9\OR\B.+_EG'
M'B/'%>\?L\_\$U/AM^RQ\6KGQ9\(;?6;?4[LZX9(Y[OS8O\`B<7.G7-W@>7_
M`*OS-(MC'&/W<?F7'_/3@`VOVKI_VB_[2T>T_8BLO@[]@E@D_M2_\;7FJ>;"
M_P#RS^SVUE'^\]_,N(_ZUY:/V7?VQOB%()_B-^U'X)\##O9^!OA?;R^7_P!<
M[G5[FX_]%U]E44`?&EU_P2'/C"<W'QN_:1_:F\:F4?O[/_A._P"P+&7_`+=M
M(MK:M#PK_P`$-/V4_"FJ)?WOP6\.>*=0C&#=>*[B\\22/]?[2EN*^NZ*`.(^
M''[//@'X)V@@^"O@CPEX20?P:-H]O9?^BHQ7;T44`?"GQ(_X(:?"WXG?$#7?
M$VL>)O'J7_B*_N-0N$@O+01QR7$GF2>4#;9\O,E9[?\`!OC\)`OR^*?B-G_K
M]L__`)&KB/BZ/V^F^*GB3_A6_P!K_P"$:_MB[_LC_D7\?9/M$GV?'F?O,>7Y
M7^L_>5@E/^"CFWD7N/\`N7JY[P_Y]GZ11IYI[.G;,Z?_`('_`,`]3_XA]/A/
M_P!#5\1O_`RR_P#D*C_B'T^$_P#T-7Q&_P#`RR_^0J\L\O\`X*+^E[_Y;U'E
M_P#!1?TO?_+>I\E/_GV=')FG_0TI_P#@?_`/4_\`B'T^$_\`T-7Q&_\``RR_
M^0J/^(?3X3_]#5\1O_`RR_\`D*O+/+_X*+^E[_Y;U'E_\%%_2]_\MZCDI_\`
M/L.3-/\`H:4__`_^`>I_\0^GPG_Z&KXC?^!EE_\`(5'_`!#Z?"?_`*&KXC?^
M!EE_\A5Y9Y?_``47]+W_`,MZCR_^"B_I>_\`EO4<E/\`Y]AR9I_T-*?_`('_
M`,`]3_XA]/A/_P!#5\1O_`RR_P#D*F'_`(-\?A1V\5?$;_P+LO\`Y"KR_P`O
M_@HOZ7O_`);U'E_\%%_2]_\`+>HY(?\`/L.3-/\`H:4__`_^`?4?['G_``2T
M\#?L7?$R\\5?#C6O%6HZG>Z;)I4D&HSV\EOY;R1R<>5;Q\YBCKZA.5`R%4>]
M?%W_``3X3]K,?&F__P"&W3,/"/\`9$GD>8='_P"/S[1%Y>?L7[S_`%7VC_IG
M7VDZE@-\8/UK:F[4SX+.U66*?MZZJ/O#4MCI10.E%,\P****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`^/?B1_P0V_99^+GC76M=\9?"F-KOQ/=_VCJ]I8ZY
MJNFZ9JD_F>;YES8VUS';229/_+2/O7M/A[]D;X=^'/BSX9\9>'O#5MIFO^#_
M``Y+X5T-[.:6VMM-TN1XY/L<=K')]G$?^CQ?\L_^68YKUFB@#SWX^?`#PO\`
MM0_!S6_`7QOTG^VO"?B>S^PZI8?:9;;[3%WC\RVDCD3I_P`LY!WKP+X*_P#!
M#K]E[]G/XH:/XQ^&7PLMXM?\//\`:-,N]4U_5=:^PR=?,BBOKJ6..3C_`%E?
M7]%`$6/.C*3=:^-]7_X(+?LGZ[XBGU&_^#UC&EUJ']K7.E0:WJMMH4MQ_P`]
M/[(BN?L7_;/RL5]FT4`>4^&/V4O`OAOXJ>+?'&AZ#''XG\;Z99:%K=W'>7'E
MW5I9^9';Q"+S/*C\OS9/]5''U-<_X9_8`^$OA7P+\+?#>B>%C;:+\$]0CU;P
M99#5;R0:-<1QR1"3S/-\RY_=W,HQ<&3_`%M>[44`?%][_P`$'_V5[_218W/P
MNN1I<6HOJ%EI\?B_6XK'1IY+D7!FL;87OEV4AD_Y]XX_^>?W,BO=/#7[)OP^
M\#V?Q+C\->&K>*/XO:A<:CXLCN+F>YCUBXN+>.VD,D<LF(_,BBCC,<?EQX]Z
M]<HH`\H_9@_9/\#_`+''PAL_`G[.NC7^B>%-/>22SL+C6+W4Q:^81^[BDO99
M)(TXXC_U8KU>BB@`HHHH`****`"BBB@#\TOBQ_P7TD^&/Q1\2^&S\+8]1_X1
MW5[S3OM?_"1B+[5]GN)(O,\K[-Q_JJQ3_P`'&UP1_P`D?CS_`-C3_P#<5?3G
MB[_@D[\`?&OBO4=8\9>"_,U36;N2\O)UUW4(Q+)))YDA\N.X$<?[R3M3#_P1
MI_9N(X\"O_X/=0_^2*YW"N?H-'&<+^SI^TPU3^O^WSYE_P"(C>;_`*(_%_X4
M_P#]Q4?\1&\W_1'XO_"G_P#N*OIG_AS7^S=_T(7_`)<&H?\`R31_PYK_`&;O
M^A"_\N#4/_DFCDKFW]I<)?\`0'4^]_\`R9\S?\1&\W_1'XO_``I__N*C_B(W
MF_Z(_%_X4_\`]Q5],_\`#FO]F[_H0O\`RX-0_P#DFC_AS7^S=_T(7_EP:A_\
MDT<E</[2X2_Z`JGWO_Y,^9O^(C>;_HC\7_A3_P#W%1_Q$;S?]$?B_P#"G_\`
MN*OIG_AS7^S=_P!"%_Y<&H?_`"31_P`.:_V;O^A"_P#+@U#_`.2:.2N']I<)
M?]`53[W_`/)GS/\`\1'$W_1'X?\`PI__`+BH/_!QQ-_T1^'_`,*?_P"XJ^F/
M^'-?[-W_`$(7_EP:A_\`)-'_``YK_9N_Z$+_`,N#4/\`Y)HY*XO[0X3_`.@.
MI]__`-N<C_P3[_X*QR?MQ?&B_P#"4G@.+PS]BTB35/M0UK[9YOER6\?E^7]G
MCQ_Q\]?^F=?:DIR`FSK7AG[.W_!/_P"$W[,'C>7Q!\"O#+:)J]U:264LXU2[
MN`8))(Y,>7++)'UBB.?:O=V&16])SM[Y\;G%;!5\0YX"FX4^S):*!P**9Y84
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110!^'O[2*?M0_P##07CG_A$Q\=O[(_X2+4/[/^PC
M5/LWV?[1)Y?E>5^[\OR_]77&E?VM?,Y'[1&/^XQ7Z#?$/_@N%\*/AS\1M9\.
MZWX?\?W%[X=U"XTNY>WL+/R99()/+,D7F7(D,>8SSC\*IM_P<"_!PG`\)_$G
M/_7A9?\`R96-1PZU#]>I9GFBI4[9:ON/@G9^UKZ?M&?EK%&S]K7T_:,_+6*^
M]?\`B(%^#7_0I_$G_P`%UA_\FT?\1`OP:_Z%/XD_^"ZP_P#DVL[0_P"?I?\`
M:N:?]"Q?<?!6S]K7T_:,_+6*-G[6OI^T9^6L5]Z_\1`OP:_Z%/XD_P#@NL/_
M`)-H_P"(@7X-?]"G\2?_``76'_R;1:'_`#]#^U,U_P"A8ON/@K9^UKZ?M&?E
MK%)L_:U]/VB_RUBOO;_B(%^#7_0I_$G_`,%UA_\`)M'_`!$"_!K_`*%/XD_^
M"ZP_^3:+0_Y^A_:F:_\`0L7W'P3L_:T]/VB_RUBC9^UIZ?M%_EK%?>W_`!$"
M_!K_`*%/XD_^"ZP_^3:/^(@7X-?]"G\2?_!=8?\`R;1:'_/T/[5S3_H6+[CS
M?_@CK_PO(?M.:U_PTF/BK_PCW_",W&S_`(2;^T/L/G_:;;R\?:?W?F^5YG3_
M`*:5^G6,<_\`+.OEG]C[_@J)X`_;3^*%UX6^%FB^*]+U"QT^35)7U2TMXXGC
M22./`,5Q)^\S**^I;9?W>W).:WH?PS\XXCKU\3CW.OA_9^1:!R**.E%6>*%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`?SB?M<#'[5?Q+'_4W:G_Z625Y]7[F>*?\`@JK^
MS_X-\6:EI'C7QJ8]7T.[?3[R`:'?R>3/')Y<@\R.WQ)^\CZBF_\`#XG]FO:,
M^.O+_P"Y?U#_`.1JXJM*F]74/VFAQ;F='#TTLNJ?U_VX?AK17[G_`/#XO]FO
M_H>/_+>U#_Y&IO\`P^0_9J_Z'G_RW]0_^1J7LJ?_`#\-O]<\S_Z%<_Z_[</P
MRHK]S?\`A\A^S5_T//\`Y;^H?_(U'_#Y#]FK_H>?_+?U#_Y&I^RI_P#/PT_U
MRS/_`*%4_P"O^W#\,J*_<W_A\A^S5_T//_EOZA_\C4?\/D/V:O\`H>?_`"W]
M0_\`D:CV5/\`Y^!_KEF?_0JG_7_;A^&5%?N;_P`/D/V:O^AY_P#+?U#_`.1J
M<?\`@L7^S7_T/'_EO:A_\C4O94_^?AG_`*YYG_T*Y_U_VX?"7_!`$G_ALOQ#
MM&<>#KLG_P`#;*OV1BEKP/\`9Z_;Z^$O[3/C6X\/_`?Q,=5U>ULSJ,\']EWE
MIFW22-#)YDL4<?66+C_;%>]KB,<GKWKKA_"L?EG%.8U\PQ[K8BG[-OH6J*!T
MHJSPPHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@#^<3]K@Y_:K^)>!@?\)=J?'I_IDE>?5^
MJ/Q4_P""`]U\3_BIXD\23_%*.R_X2+5[O5#!_P`([YOD_:+B23R_--R,_P"L
M]*Y\_P#!N5=8.WXO0G'_`%+!_P#DVO.=*HV?OV$XURBC1I4WB-O\9^9U%?II
M_P`0Y-U_T5R+_P`)C_[MI?\`B')NO^BN1?\`A,?_`';2^K5#?_7;)/\`H(_"
M9^95%?IK_P`0Y-U_T5R+_P`)C_[MH_XAR;K_`**Y%_X3'_W;1]6J!_KMDO\`
MT$?^EGYE45^FO_$.3=?]%<B_\)C_`.[:/^(<FZ_Z*Y%_X3'_`-VT?5J@?Z[9
M+_T$?^EGYE45^FO_`!#DW7_17(O_``F/_NVD/_!N3=?]%<A_\)C_`.[:/JU0
M/]=LD_Z"/PF>6_\`!`*V%S^V7X@#'_F3KO\`]+;*OV0\D$?2OBO_`()]_P#!
M)V?]ASXS:EXNF\<1>)Q?:1+I2VD>D?8L>9/;R>9YGVB3)_T;I_TT-?;(AYX[
MUWX?2G9GX]QEC\/FF8NMAY\]-DHZ44459\V%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`?
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
